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ABSTRACT  
MODULATION OF AUTOPHAGY AND SENESCENCE TO ENHANCE THE 
RESPONSE TO THERAPY IN TRIPLE NEGATIVE BREAST CANCER 
 
By Liliya Tyutyunyk-Massey, B.A.  
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2019 
Director: Dr. David A. Gewirtz, Professor, Department of Pharmacology & Toxicology 
 
Although great strides have been made over the decades in development and 
optimization of anti-cancer therapies, even highly effective drugs often fail to completely 
eliminate tumors, allowing some subpopulations to survive after treatment. Residual 
tumor cells can enter into a state of dormancy for prolonged periods of time but 
eventually are able to regain proliferative capacity and reemerge as chemotherapy-
resistant disease. Because recurrent disease is a leading contributor to patient’s 
mortality, it is paramount to identify strategies for effectively destroying residual tumor 
cells in order to eliminate (or more realistically, delay) recurrent or secondary disease. 
Cytotoxic drugs and ionizing radiation are used as standard therapies in a variety of 
cancers including hematopoietic malignancies and solid tumors. These modalities 
 xiii 
induce cell-autonomous responses to outside  stressors such as  cell death by 
apoptosis, autophagy and senescence.  
 
 
 
Senescent growth arrest is often thought to be irreversible; however, relatively recent 
studies in our laboratory as well as others both, in in-vitro and in-vivo have established 
that senescent tumor cells are able to escape growth arrest and recover proliferative 
capacity. 
Figure 1. Cell autonomous effects of anti-tumor therapies. Tumor cells upon 
treatment with chemotherapy or radiation can undergo apoptosis. Alternatively, 
therapies can induce autophagy and senescent growth arrest., which are major 
outcomes of most treatments.  Both autophagy and senescence can later result in 
cell undergoing apoptosis; however, they can also play a protective role allowing 
tumor cells to evade cell death.   
 xiv 
Autophagy is evolutionary conserved process which cells utilize in order to survive 
stressful conditions. Autophagy is generally considered to be a protective mechanism; 
however, it can take non-protective or even cytotoxic form in response to anti-cancer 
treatments. Furthermore, chemotherapy or radiation induced autophagy was shown to 
be a contributor to the immune response against tumor cells.     
In addition to direct effects on tumor cells, anti-cancer treatments are known to promote 
cell non-autonomous responses. These responses include upregulation and/or release  
of signaling molecules or membrane-bound proteins which indicate cell stress and 
mobilize the immune system against injured tumor cells.  These attractors can be tumor 
specific antigens, which are present on the surface of tumor cells or secreted factors 
such as cytokines and chemokines that activate immune cells allowing them to 
recognize and eliminate tumor cells. Significant attempts to engage the immune system 
against tumor progression have been made in recent years. In the course of our work, 
we found that enhanced autophagy as result of epigenetic modulation can play an 
important role in the immune response against tumor cells. Using a model of Triple 
Negative Breast Cancer, we were able to show increased immunosurveillance of tumor 
cells after enhanced autophagy was achieved by combining epigenetic remodeling with 
chemotherapy. Particularly, breast tumor cells in which chromatin remodeling protein  
Nucleosome Remodeling Factor NURF or BPTF was inhibited genetically, presented 
better target for Natural Killer (NK) lymphocytes following exposure to chemotherapy.  
Both, NK cell response and enhanced autophagy were shown to be necessary for 
increased sensitivity to chemotherapy in tumor bearing animals.   
 xv 
Alternative strategies are still needed in order to achieve effective clearance of residual 
tumor cell populations, as immune therapies are not always effective, particularly in the 
case of solid tumors, which can be quite adept at evading immune surveillance.  As it 
appears that the majority of anti-cancer therapies induce cellular senescence, such cells 
potentially present excellent targets. The results of our investigations showed that 
senescent cells can be eliminated by compounds specifically targeting such cells. In the 
course of our work, we were able to achieve effective clearance of tumor cells induced 
into senescence by chemotherapy or radiation by the senolytic drug ABT-263 
(Navitoclax).   In summary, autophagy and senescence alone or in concert, can be 
induced by conventional anti-tumor modalities.  Those cellular processes  are major 
outcomes of anti-cancer therapies, as they can impact success of cancer treatment, and 
deserve close consideration. Both autophagy and senescence can be modulated  
independently to enhance responses of tumors to therapy. 
 
 1 
INTRODUCTION 
A. Cellular senescence. 
Senescence was first defined as a limit to replicative capacity after which cells enter state 
of growth arrest and can no longer divide. This finite number of divisions was termed the  
Hayflick limit [1] . Another term for this phenomenon is replicative senescence that is 
associated with telomere shortening [2]. Besides normal cells reaching the replicative 
limit, there are other conditions under which cells can enter senescence. Oncogene 
induced senescence is a mechanism whereby cells enter growth arrest in order to avoid 
oncogenic transformation [3]. Stress induced senescence is caused by environmental or 
cytotoxic insult such as UV exposure, accumulation of reactive oxygen species (ROS), 
and exposure to radiation [4],[5]. Cytotoxic therapies or ionizing radiation commonly used 
as cancer treatments are known to induce senescence [6]. Although an optimal outcome 
of cancer therapy is apoptosis, a primary mechanism of cell death, senescence is 
considered a good alternative as it renders tumors arrested and can result in progression-
free disease. With this in mind, drugs were developed to specifically induce senescence. 
For example, clinically used cell cycle inhibitors achieve senescence as a primary 
outcome of treatment without causing significant DNA damage [7].                 
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A.1.  The Senescent Phenotype 
Although senescence is quite complicated, some features of senescent cells are well 
characterized. Cells that entered into senescence become large, distended and granular 
as they accumulate cytoplasmic vacuoles. 
One of the classical markers of senescence is Senescence-Associated b-Galactosidase 
or SA- b-Gal. This enzyme is localized to the lysosomes and is different from cytoplasmic  
b-Galactosidase. Up-regulation of lysosomic  b-Gal is indicative of cellular senescence 
although it does not play a role in senescence induction or maintenance [8].  
Senescent arrest appears to be due, in large part, to activation of cell cycle regulators 
such as p53, p21Cip1/Waf1 and p16INK4a. p21Cip1/Waf1 and p16INK4a inhibit Cyclin Dependent Kinases, 
responsible for cell cycle progression, and thus, induce cell cycle arrest and halt mitosis 
[9].  
Polyploidy also appears during senescence as DNA may be replicated but not followed 
by mitotic division. However, some studies show that cells that acquire polyploidy after 
exposure to chemotherapy can divide and give rise to treatment resistant populations 
[10].  
 
Chromatin remodeling is a process significantly activated in senescent cells. 
Particularly, Histone 3 Methylation on the lysine residue is most often used as a 
senescence marker.  Accumulation of senescence associated H3K9Me foci in the 
nucleus confirm chromatin changes indicative of senescent growth arrest.  Additionally, 
there are other markers such as PML (promyelocytic leukemia) bodies and 53BP1 
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protein foci [11] that are also indicative of senescence. These proteins are recruited to 
the sites of  DNA breaks .  When DNA remains unrepaired or repaired incorrectly, which 
often happens as a consequence of chemotherapy or radiation exposure, so called 
“DNA scars” appear.  These lesions are due to accumulation of repair proteins recruited 
to the site of Double Stranded or Single Stranded DNA breaks. When cells enter 
senescence with unresolved DNA damage, these proteins never dissociate from the  
DNA and form permanent foci. [12] 
Arguably the most important feature of senescent cells is Senescence -Associated 
Secretory Phenotype or SASP. The SASP has garnered significant attention in studies 
of aging, where accumulation of senescent cells was shown to be associated with 
multiple diseases. [13] [14] Composed of a multitude (over forty) pro-inflammatory 
molecules and metalloproteases, the  SASP is considered highly deleterious. 
Components of this inflammatory profile such as cytokines IL-6 and IL-8 are known to 
cause chronic inflammation, tumorigenesis and facilitate metastatic progression [15].     
      
 A.2. Evidence of proliferative recovery of the senescent cells. 
The ability of the senescent cells to escape growth arrest has been disputed and often 
dismissed, as conventional opinion has long been that senescence is irreversible. In 
addition, none of the markers that identify senescent cells actually are both necessary 
and sufficient for induction of senescence. For example, SA- b-Gal is associated with 
senescent cells, but its genetic depletion did not prevent cells from undergoing 
senescent growth arrest. [16] Similarly, cell cycle regulators such as p53, p21 and p16 
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may not be present in the cell or induced at a time when cells are clearly senescent. 
[17] 
However, more studies are being published  consistently showing escape from senescent 
growth arrest [18] .  Many studies in the literature showed that replicative and oncogene 
induced senescence are not necessarily permanent [19]. In addition, there are multiple 
examples  of cells escaping Therapy Induced Senescence [20]. For instance, escape 
from senescence was shown in a model of lung cancer cells treated with etoposide [20]. 
Similarly, the human breast cancer cell line MCF-7 also showed ability of neoplastic 
escape after treatment with Doxorubicin [21]. Despite significant evidence of reversibility 
of TIS the idea still remains controversial.  
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Figure 2. Therapy Induced Senescence. Senescent phenotype. DNA damaging 
agents and cell cycle inhibitors induce senescence in tumor cells. Senescent cells 
have a distinct phenotype: an enlarged cell body, upregulation of Senescence 
Associated b-Galactosidase, induction of cell cycle regulators such as p53, p21 and 
p16. These cells can undergo significant chromatin remodeling and become 
genetically unstable. Senescent cells secrete a plethora of signaling molecules 
collectively termed the Senescence Associated Secretory Phenotype or SASP. 
SASP molecules act on neighboring cells (including tumor tissue) in paracrine 
fashion but can also provide autocrine stimulation to the senescent cell itself. SASP 
can cause oncogenic transformation of healthy tissue and potentially drive 
neoplastic escape of senescent tumor cells.       
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B. Senolysis and senolytic agents. 
 As senescence has long been a focus of studies pertaining to aging, the concept of 
senolysis has recently achieved recognition.  Efforts have been focused on developing  
compounds that can selectively clear senescent cells without having a negative impact  
on the healthy tissue [22]. Senescent cells are known to upregulate antiapoptotic 
pathways, which is logical as they are adept at avoiding cell death [23]. This approach 
of elimination of such cells is based on inhibition of anti-apoptotic proteins, particularly 
BCL-2 family proteins that include BCL-2, BCL-XL, BCL-W and MCL-1. BCL-2 inhibition 
leads to release of proapoptotic proteins such as BAX and BAK that translocate to 
mitochondrial membrane and cause Mitochondrial Outer Membrane Permeabilization or 
formation of membrane pores, release of cytochrome-c and induction of apoptosis.  One 
such inhibitor ABT 263 or Navitoclax showed promising results when used  in aged 
animals. Here studies showed that elimination of senescent cells that accumulate with 
age can significantly improve functions of the organism that may be impaired due to 
aging [23]. Senolytic agents are proven to be quite successful in studies of cancer as 
well. This is based on the fact that senescent tumor cells up-regulate the expression of 
BCL2 family proteins (BCL2, BCL-XL and BCL-W) as a feature of senescence and as 
response to significant DNA damage, this upregulation serves as pro-survival 
mechanism [24] 
 BCL2 inhibitors such as ABT-737, ABT-263 or histone deacetylase inhibitors that work 
to reduce expression of BCL2 proteins have been shown to effectively sensitize cancer 
cells to treatments. For instance, ABT-737 given in combination with multiple 
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chemotherapeutic drugs was shown to achieve sensitization and overcome resistance. 
[25][26] [27].  ABT263 or Navitoclax was also shown to overcome resistance to 
vorinostat in lung cancer model [28]. In our studies we utilized somewhat  different 
approach. Knowing that senescent cells may rely on anti-apoptotic machinery to survive  
we use ABT263 on tumor cells that are in senescence after exposure to  chemotherapy 
or radiation. This method allows elimination of the residual senescent population which  
is resistant to apoptosis and can potentially escape growth arrest.   
Unfortunately, senolytic drugs can be quite toxic. Particularly,  ABT263 in Phase I/II 
clinical trials showed to cause thrombocytopenia while inhibiting BCL-XL in platelets [29] 
[30]. Alternative compound ABT199 (BCL2 specific) was shown to be efficacious 
against lymphoma and non-toxic to platelets [31].  However, because ABT199 is not as 
active against BCL-Xl and BCL-W it may not be as potent senolytic as ABT263 [32]. 
Therefore, there is still a need  for effective and well tolerated agents.   
 
 
C. Autophagy Mechanism  
Macroautophagy, commonly referred to as autophagy, is a process whereby some 
cellular content is sequestered into double membrane vesicles, the phagosomes, which 
later fuse with lysosomes, completing delivery of sequestered cargo for acidic 
degradation. (Figure 3) Process of autophagy occurs in three stages: initiation, 
elongation of the phagophore and fusion with the lysosome. [33] When cells are 
subjected to stressful conditions autophagy begins with formation of Beclin1/VSP34 
proteins complex. These regulatory proteins subsequently recruit multiple autophagy 
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associated proteins (ATG family proteins). This large complex works to initiate formation 
of the double membrane of the phagophore. The second stage of autophagy is 
elongation and maturation of the phagophore. At this stage Microtubule-associated 
proteins 1A/1B light chain 3B (LC3B) protein is recruited from the cytoplasm to the 
newly formed membrane. LC3BI mostly resides in the cytoplasm, but during autophagy 
induction it is cleaved and attaches to both inner and outer membranes of the 
phagophore, where it can be detected as LC3BII (cleaved and lipidated from). LC3 
serves several different functions. It facilitates phagophore elongation and works as a 
docking site for other proteins. Cellular content is gathered into the newly formed 
vesicle. [33] This process is facilitated by a Sequestosome-1 (SQSTM1) also termed as 
the ubiquitin-binding protein p62, which is able to bind ubiquitinated and marked for 
degradation cytoplasmic content and deliver it to the phagosome. During the third stage 
of autophagy mature phagosome fuses with the lysosome and undergoes acidic 
degradation. LC3BII proteins that are located in the inner membrane of the phagophore 
are degraded along with p62  found inside the vesicle. Thus, autophagy comes to 
completion and results in release of nutrients and macromolecules necessary for 
maintaining cellular homeostasis [34].     
Basal levels of autophagy, maintained by most cells, serve as a mechanism of 
homeostasis, clearance of damaged organelles and nutrient recycling. An evolutionary 
conserved process, autophagy ensures cell survival under conditions of stress such as 
nutrient deprivation or hypoxia. Baseline autophagy can also serve as a mechanism 
preventing oncogenic transformation. Studies indicate that loss of the autophagy 
regulatory gene, beclin-1, or its low expression promotes tumorigenesis in mammary 
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epidermal cells, resulting in the formation of tumors with characteristics of Triple 
Negative Breast Cancer [35], [36]. It was further shown that defects in autophagy may 
result in breast cancer pathogenesis independent of functional beclin-1. Autophagy can 
also act as a precursor to oncogene-induced senescence, [37] where senescence is a 
mechanism whereby cells can avoid malignant transformation. 
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Figure 3. The autophagic process. Upon deprivation of nutrients or growth factors, 
activation of AMPK and/or inhibition of mTOR leads to activation of ULK (Unc-51 like 
autophagy activating kinase), which phosphorylates Beclin-1, leading to VPS34 
(phosphatidylinositol 3-kinase) activation and phagophore formation. ULK functions 
in a complex with FIP200 and ATG13, whereas VPS34 function requires a regulatory 
subunit, VPS15 (p150), and Beclin-1, which further mediates the association of other 
regulatory factors such as AMBRA, ATG14, UVRAG, and BIF- 1. Multiple ATG 
proteins such as ATG5 and ATG7 constitute two "ubiquitin-like conjugation systems" 
that catalyze the formation of phosphatidylethanolamine (PE)-conjugated LC3 (LC3-
II) and direct its proper incorporation into the phagophore membrane, where it serves 
as docking site of adaptor proteins (and bound cargos). The closure of an elongated 
phagophore marks the formation of a mature autophagosome, which eventually 
fuses with a lysosome, leading to cargo degradation and recycling of nutrients and 
metabolites. Ub, ubiquitin.		Adapted from (Cicchini, 2014) 
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C.1. Autophagy as response to anti-tumor modalities 
The nature of autophagy as a response to anticancer therapy can vary. Cell 
autonomous effects of autophagy can either provide cytoprotection or be non-protective. 
Although the mechanism of autophagy induction may vary, all modalities that are used 
to treat breast cancer trigger autophagy.  Targeted therapies such as Estrogen 
deprivation or Her2 receptor blockade induce protective autophagy [38],[39],[40] which 
serves as a mechanism of drug resistance.  Blocking this form of autophagy with 
pharmacologic agents such as chloroquine results in cell sensitization to therapy [40]. 
Chemotherapy and radiation, in addition to promoting cytoprotective autophagy, have  
been shown to induce non-protective autophagy that may not change outcome of 
treatment. [41] In addition, a cytotoxic form of autophagy also exists. [42] The nature of 
autophagy in response to anti-cancer treatments is very important in terms of 
therapeutic outcomes. Because autophagy is assumed to be  a survival mechanism 
many studies are focused on blocking it in order to potentiate therapy. However,  
blocking non-protective or cytotoxic autophagy may be of no benefit or even detriment 
to the patient.  There is no  known method to predict the nature of autophagy as it can 
depend on cell lines and treatment administered.      
 
 
C.2. Cell autonomous and cell non-autonomous effects of doxorubicin. 
Doxorubicin (Dox), a topoisomerase II inhibitor, commonly used to treat a variety of 
malignancies, including breast cancer, was identified among other chemotherapy 
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compounds to promote immunogenic cell death (ICD) [43] This means that, in addition 
to cell autonomous cytotoxicity, this drug has cell non-autonomous effects, making 
tumor cells more immunogenic [44] The primary cell autonomous effect of doxorubicin is 
DNA damage that promotes autophagy, senescence and/or apoptosis [45] Apoptosis by 
itself, although a desirable outcome of treatment, is considered sterile cell death and 
does not evoke an immune response. Autophagy and senescence, on the other hand, 
when coupled with apoptosis, have both been shown to be involved in eliciting immune 
responses against tumor cells [46] 
 
C.3. The role of autophagy in immunogenic cell death. 
Immunogenic cell death takes place when apoptosis is accompanied by Endoplasmic 
Reticulum (ER) Stress  and robust autophagy. [47][48]Together these processes lead to  
release of several signaling molecules termed Danger Associated Molecular Patterns or 
DAMPs is initiated. (Figure 4)  DAMPs most often include ATP (Adenosine 
triphosphate),  Calreticulin (CRT) and High mobility group box 1 protein (HMGB1) 
[49][50][51]  
Translocation of CRT, the most abundant ER protein, from the ER inner membrane onto 
the surface of the plasma membrane is associated with significant ER stress. This is  
caused by accumulation of misfolded proteins on its inner membrane, which is often can 
occur due to DNA damage and impaired transcription. CRT located on the outer plasma 
membrane can be detected by immune cells. As a result, CRT translocation promotes 
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phagocytosis of tumor cells by antigen presenting cells that subsequently prime CD4+ 
and CD8+ T-cells. [52]  
The antitumor immune response can be stimulated by secretion of ATP [53],[54] in 
addition to calreticulin (CRT) translocation, as both can attract immune cells into the tumor 
bed [51][52]. The release of ATP from the tumor cells depends on induction of autophagy 
[55]. ATP  binds to cell surface receptors on the surface of the immune cells and acts as 
an attractant and activator of dendritic cells (DC) and macrophages [55].   
       Accumulation of HMGB1 and its release has been associated with both, autophagy and 
apoptosis [56] This protein has also been shown to promote anti-tumor immune 
response as high levels of HMGB1 correlated positively with tumor infiltration by 
Cytotoxic Lymphocytes. [57]        
Results of several studies indicated that anticancer therapies which promote marginal 
apoptosis, but significantly elevated autophagy, produce profound antitumor effects in-
vivo [49] This observation led to the consideration of cell non-autonomous effects of 
autophagy as important outcomes of cancer treatment in terms of anti-tumor immune 
response. In fact, clinical data suggests that autophagy does play an important role in 
anti-tumor immunity. Analysis of tissue obtained after breast tumor patients had 
undergone resection revealed a positive correlation between accumulation of LC3 puncta, 
indicative of autophagy, and tumor immune infiltration. In particular, the absence of LC3 
puncta, a durable marker of autophagy induction, was associated with high levels of 
immunosuppressive cells such as Regulatory T cells or T-regs. [58] 
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Besides its pivotal role in promoting ICD, autophagy is instrumental in adaptive antitumor 
immunity which relies on cytotoxic lymphocytes that have to be primed against tumors by 
Dendritic cells or Natural Killer (NK) cells.  Autophagy has been shown to promote antigen 
presentation by both MHC class I and MHC class II molecules [57]. Autophagy is also 
proven to play an important role in antigen cross-presentation by DC to cytotoxic T-cells 
[57], [59].  
 
 
 15 
 
 
 
 
 
 
 
Figure 4. Cell autonomous and cell non-autonomous effects of chemotherapy 
and or radiation treatments. Cytotoxic stress can induce apoptosis which by itself, 
rarely causes  immune response. When autophagy and ER stress responses are 
induced, they lead to release of signaling molecules which are part of Danger 
Associated Molecular Patterns or DAMPs.  Release of DAMPS by apoptotic cells 
activates the immune response and clearance of injured or dying tumor cells. This 
process of immunogenic cell death reflects the cell non-autonomous effect of 
radiation, chemotherapies and some targeted therapies.          
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C.4.   Involvement of NURF (BPTF) in cancer and immunosuppression. 
Epigenetic modulators play a significant role in cancer by promoting global changes in 
chromatin that can lead to dysregulation of the genome [60]. One such protein, the 
Nucleosome Remodeling Factor (NURF), is an ATP-dependent chromatin remodeling 
enzyme that is responsible for sliding the nucleosome along the DNA, thus regulating 
gene expression. There are three subunits of mammalian NURF, specifically 
pRBAP46/48, SNF2L and the largest and most significant for DNA binding, the 
bromodomain PHD-finger containing transcription factor (BPTF). [61] BPTF was found 
to be overexpressed in several types of cancers. BPTF is implicated in therapy 
resistance as a factor that can promote expression of anti-apoptotic and pro-
proliferation proteins such as BCL-2 and c-Myc. In addition, BPTF was found to be 
involved in suppressing CD4+ and CD8+ T-cell mediated antitumor immunity by 
negatively affecting  antigen presentation [62].  In addition, BPTF was found to be 
involved in immune inhibition by  suppressing CD4+ and CD8+ T-cell mediated antitumor 
immunity [62].  Genetic depletion of BPTF by shRNA resulted in a significant decrease 
in tumor weight when mouse mammary tumor cells  67NR and 66c14  were injected into 
syngeneic mice. It was also shown that BPTF depleted cells are more susceptible to NK 
cell mediated cytotoxicity [63].  
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D. Dissertation Aims 
Specific Aim 1: To show reversibility of Therapy Induced Senescence in Triple 
Negative Breast Cancer model in-vitro and in-vivo .  
We hypothesized that Therapy Induced Senescence (TIS) is reversible as tumor cells 
are capable of regaining proliferative capacity, a mechanism that facilitates disease 
recurrence. Prolonged growth arrest associated with Therapy Induced Senescence and 
recovery can be a mechanism of tumor dormancy. Knowing that senescent cells can be 
subject to immune surveillance we planned to determine if intact immune system can 
prevent proliferative recovery of  senescent tumor cell population following implantation 
into animals.   
In order to show that Therapy Induced Senescence is reversible, we evaluated the 
phenotype and response of the 4T1 murine breast carcinoma cell line, which is an 
established model of TNBC, following chemotherapy. Senescence was induced in these 
cells by a clinical dose of Doxorubicin (Dox), a drug that has been on the market for 
over forty years and still remains widely used as a chemotherapy for a variety of solid 
tumors. We confirmed induction of senescence by microscopy, detecting morphological 
changes such as cell enlargement, flattening, increased granularity and elevated 
expression of SA-b-Gal using X-Gal dye. In addition, the percent of senescent cells in 
the population was quantified by Flow Cytometry. Other assays utilized to observe 
senescence and proliferative recovery included cell cycle analysis and time course 
growth curves. We were also able to purify the senescent population based on SA-b-
Gal fluorescence and observe cell viability and cell number over time. To establish that 
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senescent cells are able to recover and form tumors in-vivo, purified senescent 4T1 
were injected into the mammary fat pad of syngeneic BALB/C mice (immune 
competent) and the NOD scid gamma (NSG) mice (immune compromised). Comparing 
tumor growth  in  BALB/C and NSG animals allowed to evaluate the immune response 
against senescent tumor cells.    
Specific Aim 2: To show that cells induced into senescence by chemotherapy or 
radiation are sensitive to elimination by BCL-2 family proteins inhibition and can 
be cleared by ABT263. We hypothesized that breast cancer cells upregulate 
antiapoptotic proteins such as BCL-2, BCL-XL, BCL-W and MCL-1. These proteins 
allow cells to evade cell death while in therapy induced growth arrest. We predicted that 
chemotherapy treated cells are a good target for elimination by senolytic agents.  
Exposure to ABT263 will result in increased apoptosis in cells  and will prevent 
proliferative recovery.   
In order to evaluate the effects of senolytic agents, MDA-MB-231 human breast cancer 
cells were induced into senescence by clinical dose of Doxorubicin (Dox) [64]. Variety of 
assays were employed  to confirm induction of senescence including  SA-b-Gal 
staining,  immunofluorescence images showing methylation of Histone 3 on lysine 
residue and cell cycle distribution analyzed by Flow Cytometry using  Propidium Iodide. 
We used ABT263 (Navitoclax) to achieve senolysis in Dox treated MDA-MB-231. 
Induction of apoptosis by ABT263 was analyzed by Flow Cytometry. In addition, 
cleavage of executioner protein Caspase-3 and PARP protein (which is cleaved by 
Caspase-3 during apoptosis)  were analyzed by Western Blotting. Induction of 
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senescence in-vivo was evaluated after implantation of cells into NSG mice that were 
subsequently treated with Dox when measurable tumors appeared. Tumor tissue was 
collected and stained for SA-b-Gal. To confirm ABT 263 activity in-vivo after Dox 
treatment, the animals received Navitoclax by oral gavage. Apoptosis in tumor tissue 
was detected by immunofluorescence showing PARP cleavage. 
Specific Aim 3: To show that enhanced autophagy induced by chemotherapy in 
breast tumor cells is a major contributor to anti-tumor immune response. We 
hypothesized that combining epigenetic remodeling and chemotherapy would lead to 
enhanced autophagy which in turn, can serve as a mechanism of sensitization of tumor 
cells to immune surveillance and immune clearance.  
 We employed a BPTF (NURF) knock down (KD) [63] to enhance sensitivity of breast 
tumor cells to anti-cancer drugs and immune surveillance. Effects of NURF inhibition on 
cells in culture were assessed by colony formation, DNA damage assay, Apoptosis, 
Senescence and Autophagy. Assessment of the immune response to genetic depletion 
of BPTF was achieved by exposing Dox treated tumor cells to Natural Killer (NK) 
lymphocytes or otherwise co-culturing non-treated 4T1 targets with NK cells previously 
exposed to conditioned media (CM) from chemotherapy treated BPTF Wild Type (WT) 
and BPTF knock down (KD) cells. To show dependence of an enhanced immune 
response against BPTF KD tumor cells on NK cell surveillance in-vivo, 4T1 tumor cells 
were implanted into immune competent animals and animals in which NK cells were 
depleted by monoclonal antibody and tumor growth was monitored over time. To 
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confirm involvement of autophagy in enhanced immune system activation against 
NURF KD tumors, autophagy was inhibited by shRNA against the Atg5 gene.  
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A. Introduction 
 
Cellular senescence is a mechanism of growth arrest, most often associated with 
telomere degradation. Senescence caused by telomere shortening is associated with 
aging and is referred to as replicative senescence. In contrast, premature senescence 
not associated with telomere status occurs in response to oncogene mutation (oncogene 
induced senescence) and serves as a mechanism preventing cells from undergoing 
malignant transformation and become cancerous. Premature senescence can also be 
induced by extensive DNA damage caused by oxidative stress, UV exposure, radiation 
or cytotoxic agents (including chemotherapy). Senescent cells remain metabolically 
active but do not proliferate and are unresponsive to growth stimuli. [64] Cells are 
characterized by enlarged flattened morphology, upregulation of proteins involved in cell 
cycle control (p21, p53, p16), polyploidy, chromatin remodeling and elevated expression 
of the  𝜷-Galactosidase enzyme [65],[66].  
Although senescence is generally considered irreversible, there are, however, cases 
when cells are able to escape growth arrest and reenter the cell cycle. Cells that escape 
chemotherapy induced senescence are characterized by increased genomic instability, 
can acquire multiple mutations and often are resistant to further treatment.  
Senescent sells secrete over forty signaling molecules (cytokines, chemokines and 
growth factors) and metalloproteases that together comprise the Senescence 
Associated Secretory Phenotype or SASP.  Although oncogene or DNA damage 
induced growth arrest is considered beneficial, as it prevents tumorigenesis, the SASP 
is largely deleterious.  Components of the SASP can drive chronic inflammation, cause 
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tissue and organ damage, and drive secondary malignancies by inducing oncogenic 
transformation of neighboring senescent cells [67].  
Senescent cells, however, have some positive features as well. For example, these 
cells were shown to be a target of robust immune surveillance and can be eliminated in 
the course of an immune response that follows therapy induced cytotoxic damage [68] 
[69]  
In this work we show that breast tumor cells induced into senescence by Doxorubicin 
(Dox), a drug that is often used to treat breast cancers, undergo a prolonged growth 
arrest from which they were able to escape and form de-novo populations. To confirm 
that new colonies actually arise from senescent cells rather than ones that never 
stopped dividing, we isolated pure population of senescent cells by Flow Cytometry 
Sorting. Senescence- enriched cells remained arrested for a finite period of time, but 
eventually escaped, giving rise to new populations of tumor cells. Escape from 
senescent growth arrest was observed both in-vitro and in-vivo. Sorted senescent cells 
implanted in animals remained dormant for a period of time after which growing tumors 
were detected.     
Given the crucial role of the immune system in tumor development, it was important to 
determine whether senescent tumor cells can also recover in an immunocompetent 
animal. To address this question, we implanted cells induced into senescence using 
doxorubicin and enriched based on prominent 𝜷-Gal staining in both immune competent 
and immune compromised animals.  Rates of tumor formation were compared between 
4T1 cells implanted into a syngeneic strain of BALB/c genetic background mice with 
intact immunity and NOD/SCID/Ifrg2r-/- (NSG) mice lacking an immune system. Our 
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results suggest that an immune response does in fact play a role in limiting senescent 
cell’s tumorigenic potential.  
 
B. Materials and Methods 
 
Cell Lines. 4T1 cells were obtained from the American Type Culture Collection 
(Manassas, VA). 4T1 mouse mammary tumor cells were maintained in DMEM 
supplemented with 10% fetal bovine serum (Thermo Scientific, SH30066.03) 100 U/ml 
penicillin G sodium (Invitrogen, 15140–122), and 100 μg/ml streptomycin sulfate 
(Invitrogen, 15140–122) at 37º C and 5% CO2. Adriamycin (Doxorubicin hydrochloride) 
was purchased from Tocris Bioscience (2252), drug was resuspended in DMSO 
according to the manufacturer’s instruction. 
Cell Viability. Growth curves were determined by counting viable cells based on trypan 
blue exclusion at various time points after treatment. Cells were harvested using trypsin, 
stained with 0.4% trypan blue (Sigma, T8154), and counted using a hemocytometer under 
phase contrast microscopy.  
SA-β-galactosidase Staining. SA-β-gal labeling was performed as previously described 
by Dimri et al. [70] Images were generated using a bright field by Olympus inverted 
microscope (Olympus inverted microscope IX70, 20x objective, Q-Color3™ Olympus 
Camera; Olympus, Tokyo, Japan). 
       The C12FDG staining protocol was adopted from Debacq-Chainiaux [72] 72 hours after 
Doxorubicin removal, cells were exposed to bafilomycin A1 (100 nM) for 1 h, followed 
by incubation with C12FDG (33 µM) for 2 h. Cells were harvested, washed with cold 
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PBS, and analyzed by flow cytometry (using BD FACSCanto II and BD FACSDiva 
software at the Virginia Commonwealth University Flow Cytometry Core Facility).  
For the enrichment assay, 2 x 106 cells 4T1 cells were seeded in 150 mm cell 
culture dishes, allowed to adhere overnight, then treated with 1µM Doxorubicin for 2 
hours. Three days after drug exposure, cells were pre-treated with bafilomycin A1 (100 
nM) for 1 h, followed by incubation with C12FDG in complete medium for 2 h. Cells were 
then harvested and sorted by flow cytometry based on size, granularity and intensity of 
C12FDG stain. 
Animal Studies. NOD/SCID/Ifrg2r-/- (NSG) and BALB/c (syngeneic strain) mice were 
purchased from Jackson laboratory and housed under pathogen-free conditions 
according to the Virginia Commonwealth University IACUC guidelines. To test for 
recovery potential of senescent cells, enriched high-C12FDG-positive 4T1 cells were 
suspended in sterile media (2.5×105) and injected into both the right and left mammary 
fat pads of 6-8 week old female NSG and BALB/c mice. Tumor volume was measured 
every two days with calipers (tumor volume was calculated using the following equation: 
V = length × width^2 × 0.5).   
 
C. Results  
 
Cells induced into senescence in-vitro are able to regain proliferative capacity 
following growth arrest. 
Clinical concentrations of Doxorubicin induce profound senescence in the majority of 
4T1 tumor cells, indicated by the characteristic morphology and the positive SA-β-gal 
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staining (Figure 5A) In addition, senescence was quantified by Flow Cytometry, 
showing that 80% of cells were C12FDG positive (Figure 5B). Analysis of cell cycle 
distribution showed that the majority of cells arrested in G2 with a high percent 
polyploidy (Figure 5C), profile consistent with senescence. Figure 5D indicates that the  
population of 4T1 exposed to Doxorubicin enter a state of prolonged growth arrest 
followed by proliferative recovery. (Figure 5D) 
 
 
 
 
 
Figure 5. Evidence of senescence and proliferative recovery in breast cancer 
cells in-vitro. A.  SA-β-galactosidase staining (20x objective) in 4T1 breast tumor 
cells following exposure to 1 µM doxorubicin for 2 hours B. Flow cytometry 
quantification of senescence based on C12FDG staining (SA-β-gal positive cells) 
72hours after doxorubicin (1 µM) exposure C. Cell cycle distribution analysis by 
Flow Cytometry based on Propidium Iodide nuclear stain.  Growth arrest followed 
by proliferative recovery in 4T1 cells after exposure to Dox. 
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Senescent cells were enriched by Flow Cytometry sorting (Figure 6A) to 
generate a pure population before cells could be implanted into mice. We confirmed 
enrichment using Image Stream Analysis that allows the visualization of individual cells 
in the mass population (Figure 6B) Again, SA-β-gal cell sorting and reseeding 
demonstrates that recovery also occurs from the highly C12FDG positive 4T1 cells after 
doxorubicin-induced senescence (Figure 6C). These studies confirm that senescence-
like arrest can be succeeded by proliferative recovery in the 4T1 model of breast cancer 
in vitro.  
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SA-β-gal positive cells have the potential to form viable tumors in the mouse 
model of breast tumor cells induced into senescence by doxorubicin. 
To assess the capacity of the senescent 4T1 breast tumor cells to form tumors   
in vivo, the same number of either untreated or FACS-purified senescent 4T1 cells were 
implanted into the mammary fat pad of immune competent syngeneic BALB/cJ mice or 
immune compromised NSG mice. Tumors were generated in both sets of mice, in 
support of the premise that senescent tumor cells can re-emerge into a proliferative 
state. However, monitoring tumor growth over time, we observed a significant delay in 
recovery of tumor growth from senescent 4T1 cells (time to palpable growth between 
19-21 days) compared to untreated controls (7 days) (Figure 7). Furthermore, studies in 
immunocompromised NSG compared to immune competent BALB/c mice  
demonstrated a significant delay in tumor growth in immune competent animals  while  
accelerated  tumor recovery for the senescent cells between days 25 and 33 was seen 
in immune compromised mice.  Taken together, these results indicate that the immune 
system is likely capable of maintaining growth arrest in the senescent tumor cells while 
Figure 6.  Enrichment and recovery of senescent cells.  A. Cells were pre-treated 
with 100 nM Bafilomycin to block lysosomal acidification and then stained with C12FDG 
dye for 2 hours. Cells were analyzed by Flow Cytometry and two populations SA-β-gal 
negative and positive were defined. Cells were sorted based on size and the intensity of  
C12FDG and 25% of cells considered “most senescent” were isolated. B. Populations of 
non-treated controls, senescent cells pre-sort and post-sort were visualized using 
ImageStream system and images of individual cells in the population were taken. C.  
Senescent enriched cells collected as result of sorting procedure were reseeded in 6-well 
plates and monitored for recovery over time. Number of viable cells was determined 
using trypan blue at indicated time points.         
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tumor formation is unrestrained in immunodeficient animals even when outgrowth is 
occurring from a previously senescent tumor cell population.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Evidence of proliferative recovery of senescent enriched breast 
cancer in cells in-vivo. Tumorigenic potential of enriched senescent cells in-vivo in 
immune competent and immune compromised animals (n=8). Non-treated controls 
and enriched senescent 4T1 tumor cells were injected into mammary fat pad of 
BALB/c (intact immunity) and NSG (immune compromised) at number 2.5*105 in 50 
µL of DMEM. Animals were observed for 33 days after injections and caliper 
measurement of tumors were taken every other day. Tumor volume was 
determined using following formula: V=W2*L*0.5. After NSG mice baring tumors 
formed by enriched senescent cells reached humane endpoint (2000 cm3) study 
was terminated and animals were humanly euthanized.      
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D. Discussion 
 
In addition to desirable cell death by apoptosis, conventional anti-cancer therapies induce 
a variety of responses such as growth arrest, senescence and autophagy, the latter of 
which can serve as either a protective or cytotoxic mechanism. Irreversibility of 
senescence has been an accepted paradigm in the scientific literature for many years. 
Senescence as an outcome of therapy is considered a viable alternative to apoptosis, 
largely because it does result in progression-free disease, albeit temporarily. However, 
emerging data form our laboratory and the work of others suggest that senescence is not 
a permanent, but rather transient growth arrest. [72] ,[73],[74]It is not yet known why some 
cells stop dividing permanently in response to therapy and others are able to escape 
senescent arrest and proliferate. Heterogeneous responses are most likely associated 
with genomic instability of cells induced into senescence by cytotoxic therapies. [75] The 
very fact that senescent cells are able to conserve or regain proliferative capacity is 
critically important to keep under consideration when defining Therapy Induced 
Senescence, especially in the pre-clinical and clinical models.  
The capacity of cells derived from the senescent population to form tumors in 
animals suggests that tumorigenic potential is maintained. Our study shows that when 
animals are challenged with enriched SA-b-gal positive cells, immune competent mice 
form tumors at a notably slower rate than immune compromised mice. This observation 
suggests that senescent cells can be cleared by the immune system, at least at early 
post-injection time. Still, clearly, the cells are able to escape immune surveillance.  
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Finally, it is known that tumors exposed to cytotoxic chemotherapies can either 
stimulate or inhibit immune cell function, in part through the promotion of senescence 
[76], [77]. These activities can be tumoricidal such as by upregulation of stress ligands 
[78] and tumor antigens recognized by effector CD8 T and NK cells [80] and the secretion 
of immune stimulatory cytokines such as IFNγ and CCL5, which are components of the 
SASP (70). Conversely, senescence can be immune-inhibitory, in part through direct 
suppression of immune cell activity (e.g. IL-4. IL-13), or indirectly through the amplification 
of immune suppressor cells (M2 macrophage, Treg and MDSC). [80] Some 
chemotherapies and radiation also stimulate the antitumor immune response through a 
process of immunogenic cell death (ICD) by the secretion of danger associated molecular 
pattern (DAMP) molecules (e.g. HMGB1 and ATP secretion, cell surface calreticulin and 
Hsp70) that stimulate antigen uptake and cross presentation of tumor antigens by antigen 
presenting cells (APC). [81] These activities in turn prime tumor reactive CD8 T cells, 
which improve the adaptive antitumor immune response [81]. Studies are currently in 
progress to more specifically define the nature of the immune response against cells 
induced into senescence by chemotherapy.  
 
E. Future directions 
 
Senescence appears to potentially be a model of tumor dormancy and disease 
recurrence. Although the conventional opinion is that dormant tumors are quiescent 
because they can re-enter the proliferative stage, involvement of senescence in recurrent 
disease cannot be underestimated.  Single cell analysis of a sorted population of 
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senescent cells is necessary to determine what factors may drive senescent cells to enter 
neoplastic escape. Mechanistic studies also should be considered. For example, 
association and dissociation of RB/E2F complex which is a decisive factor in cell cycle 
progression. It is apparent that in some cells senescence is rather transient, which can 
be attributed to epigenetic alteration. Changes to epigenome could be monitored while 
cells enter senescence following chemotherapy, remain in prolonged growth arrest and 
proliferate when able to escape senescence.    
       We also saw that although immune system appears to slow tumor progression by 
presumably eliminating senescent cells, eventually, some population of cells is able to 
overcome immune surveillance. To prevent this escape of tumor cells from the  immune 
system, combination of senescence inducing agents with immunostimulatory treatments  
such as checkpoint blockade  PD-1 inhibitors could be explored [82], [83]. 
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A. Introduction 
Despite the ability of chemotherapy (and/or radiation) to eliminate the majority of tumor 
cells, some residual surviving cells may be able to escape cell death by entering into a 
prolonged senescence-based growth arrest. In addition to apoptosis, the majority of anti-
cancer therapies induce senescence that has long been considered to be a favorable 
outcome of treatment due to its perceived irreversibility. [84] However, accumulating 
studies in the literature demonstrate that therapy induced senescence may reflect one 
form of tumor dormancy and disease recurrence, when senescent cells are able to regain 
proliferative capacity. [85] Tumor cells that escape dormancy often demonstrate an 
aggressive phenotype and are refractory to further treatment. [86] During the course of 
studies in our own laboratory we were able to show that purified population of senescent 
cells can recover in-vitro and most importantly give rise to tumors when injected in 
animals. Senescent cells are characterized by a specific (though often heterogeneous) 
secretory profile (Senescence Associated Secretory Phenotype or SASP), some 
components of which have been shown to promote tumorigenesis and may assist in 
neoplastic escape after therapy. [87] In models of aging and age-related diseases 
senescent cells were proven to be major contributors. Deleterious effects of senescence 
are most often attributed to the SASP. Thus, it is important to consider that, even in cases 
when residual tumor cell population remains growth arrested after treatment; the 
inflammatory profile of those cells still presents significant concerns in terms of  negative 
effects on the patient’s body. [88] 
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One of the mechanisms by which senescent cells are able to escape cells death is their 
ability to upregulate anti-apoptotic proteins, specifically of the BCL-2 family [89],[90]. 
These proteins present excellent targets in attempts to eliminate senescent cells. In 
models of aging targeting senescent cells, the use of senolytic agents has been shown 
to lead to considerable improvement of outcomes [91].  
In the current work, we utilize the BCL-2 protein family inhibitor, ABT 263, in order to 
selectively clear breast tumor cells induced into senescence by the chemotherapeutic 
agent doxorubicin.  MDA-MB-231 human breast cancer cells (a model of triple negative 
breast cancer) were induced into senescence upon exposure to a clinically relevant 
concentration of doxorubicin (Dox). While a fraction of the MDA-MB-231 cell population 
underwent cell death, a large subpopulation entered into a state of prolonged growth 
arrest that lasted for several days, after which the cells recovered proliferative capacity 
and formed colonies. At the time points when cells were arrested, prominent 
Senescence Associated β-Galactosidase staining, H3K9 Methylation  and polyploidy 
were detected, markers indicative of senescence. [93] Cells induced into senescence 
and treated with ABT263 overnight showed a significant increase in apoptosis  
quantified by flow cytometry and confirmed by Western Blot analysis of apoptosis 
markers Cleaved Caspase-3 and cleaved PARP.  Cells exposed to ABT 263 after 
therapy did not regain colony forming capabilities.  Tumor tissue collected from mice 
that received injections of Dox were positive for β-Galactosidase staining, observation 
consistent with senescence induction in cell culture. Results obtained from in-vivo study 
confirms that induction of senescence occurs in tumors following treatment with 
chemotherapy. In addition, tumor tissue collected from animals that received ABT263 
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showed increased apoptosis detected by immunofluorescence using anti-cleaved PARP 
antibody.  We, therefore, postulate that senescence and escape from senescence may 
represent a form of tumor dormancy and disease recurrence, respectively. 
Consequently, it appears that ability of ABT263 to eliminate  senescent cells in-vitro and 
in-vivo following chemotherapy or radiation warrants its use as complementary 
approach to conventional treatments.  This strategy might prevent senescent cells from 
neoplastic escape and induce cell death in order to completely eliminate residual tumors 
and thereby interfere with disease recurrence.  
 
D. Materials and Methods 
Cells and drug treatments 
The MDA-MB-231 cells were purchased from ATCC. Cell were maintained in DMEM 
supplemented with 10% (v/v) fetal bovine serum, 100U/ml penicillin G sodium, and 
100µg/ml streptomycin sulfate  at 37ºC and 5% CO2. Doxorubicin, ABT-263 were 
suspended in DMSO and administered in the dark at concentrations 0.75µM (Dox) and 
2µM (ABT263). Cells were not exposed to more than 0.2% DMSO. Radiation was 
performed using a 137Cs irradiator.  
Cell viability  
Cells were plated at a known cell number in six-well plates, incubated overnight, and 
then treated with chemotherapy or radiation. After drug was removed, or radiation 
terminated, cells were washed in PBS and allowed to recover in fresh media. Cell 
viability was determined using a hemocytometer at the indicated time points. Media was 
replenished every 48 hours.  
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SA-ß-galactosidase staining and C12FDG Quantification 
Cells were seeded in six-well, 60 mm culture dishes, incubated overnight, treated, and 
then assessed for SA-ß-galactosidase expression at the indicated time points. 
Histochemical staining of staining was performed using  X-Gal  chromogenic substrate to   
SA-b-gal that releases color and stains senescent cells blue.  Images were taken 
Olympus inverted microscope (Olympus inverted microscope IX70, 20x objective, Q-
Color3™ Olympus Camera; Olympus, Tokyo, Japan) Quantification of SA-ß-
galactosidase positive cells was performed by flow cytometry base of  C12FDG fluorescent 
staining. Four days after Doxorubicin removal, cells were exposed to bafilomycin A1 (100 
nM) for 1 h, followed by incubation with C12FDG (33 µM) for 2 h. Cells were harvested, 
washed with cold PBS, and analyzed by flow cytometry (using BD FACSCanto II and BD 
FACSDiva software at the Virginia Commonwealth University Flow Cytometry Core 
Facility).  
Cell cycle analysis   
Cells were seeded in either six-wells or 10 cm plates, depending on the cell line, and 
incubated overnight. After treatment, at the indicated time points, cells were collected 
and fixed with 70% ethanol, washed with PBS, and then stained with Propidium Iodide 
(PI) staining solution (50µg/ml PI, 4 mM sodium citrate, 0.2mg/ml DNase-free RNase A, 
and 0.1% Trition-X 100) for 1 hour in the dark at room temperature. DNA content was 
then assessed by flow cytometry using BD FACSCanto II and BD FACSDiva software at 
the VCU flow cytometry core facility.  
Annexin V/PI apoptosis staining 
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Cells were seeded into six-well plates, incubated overnight, and then treated. At the 
indicated time points, both floating and adhered cells were harvested, washed with 
PBS, and stained  in 300 µl 1X binding buffer with 3 µl Annexin V-APC (allows to 
identify phosphatidylinositol displayed in the outer membrane of cells undergoing early 
stages of apoptosis  ) and 3 µl  nuclear dye 7-AAD (allows detection of compromised 
cellular membrane) for 15 minutes at room temperature and then analyzed. Staining 
was analyzed by flow cytometry using BD FACSCanto II and BD FACSDiva software at 
the VCU flow cytometry core facility.  
Immunofluorescence and Immunohistochemistry 
For H3K9Me3 immunofluorescence, cells were seeded into 4-well chamber slides, 
incubated overnight, and then treated. At the indicated time points, cells were fixed with 
3.7% formaldehyde for 10 minutes at room temperature and then made permeable by 
incubation with 0.5% Triton-X 100 for 10 minutes at room temperature. Slides were 
blocked with 5% BSA in PBS for at least one hour. The primary anti-H3K9Me3 antibody  
was used at 1:500 in 5% BSA overnight at 4ºC, followed by the secondary goat anti-
rabbit antibody conjugated to Alexa-Fluor488 at 1:500 in 5% BSA for 2 hours at room 
temperature. Slides were counterstained and mounted with Fluoroshield mounting 
medium with DAPI. Images were taken on an Olympus inverted microscope  at 100X.  
Western Blotting 
Protein lysates were collected with CHAPS buffer (and then quantified by the Bradford 
method. Equal amounts of protein were diluted with sample buffer, boiled, and then 
loaded onto an SDS-PAGE gel. Proteins were then transferred onto a PDVF 
membrane. The membrane was blocked with either 5% BSA or 5% milk in TPBS for at 
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least 1 hour at room temperature. Primary antibodies were incubated at 4ºC overnight at 
1:1000 cleaved caspase 3, and cleaved PARP or 1:4000 GAPDH  in 5% BSA in TPBS. 
The secondary antibody (anti-rabbit-HRP) was used at 1:2000 in 5% BSA for 2 hours at 
room temperature. Signal was detected using Pierce ECL Plus () or SuperSignal West 
Femto Maximum Sensitivity ECL, depending on the protein of interest.  
 
 
C. Results 
Induction of senescence in MDA-MB-231 Triple Negative model in response to 
doxorubicin and radiation.  
 DNA damaging agents such as Dox  and radiation conventionally used in the treatment 
of TNBC, often induce senescence in tumor cells as a primary response [94]. To induce 
senescence in human triple-negative breast adenocarcinoma (MDA-MB-231), we used 
a clinically relevant concentration of doxorubicin (Dox) or radiation (IR). Figures 8A and 
8B confirm induction of senescence in MDA-MB-231 cells in response to Dox (0.75 μM) 
and IR (8 Gy) based on increased SA-β-gal expression and  morphological changes 
that included  significant increase in size, flattening and granulation. In addition, 
accumulation of the senescence associated heterochromatic foci H3K9Me3 was also 
observed.  Cell cycle distribution in cells treated with Dox shifted  from G0/G1 and S 
phases, indicative of proliferation,  to G2 phase arrest with accumulation of polyploid 
cells (more than 50 %) (Figure 8C) a profile associated with senescence. These results 
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indicate that exposure of tumor cells to either doxorubicin or radiation results in a 
senescence-mediated growth arrest.  
 
 
 
 
 
Figure 8.  Induction of senescence in human TNBC cell line MDA-MB-231 by 
doxorubicin or radiation. A.  SA-β-galactosidase staining (20x objective) and 
heterochromatic H3K9Me3 foci formation (100x objective) in cells following 
exposure to 0.75 µM doxorubicin for 2 hours. B. Flow cytometry quantification of 
senescence based on C12FDG staining (SA-β-gal positive cells) 4 days after 
doxorubicin (0.75 µM) and radiation (8Gy) exposure. C. Cell cycle distribution 
analysis by Flow Cytometry based on Propidium Iodide staining  in MDA-MB-231 
cells after exposure to Dox. All images are representative fields from at least three 
independent experiments, and all quantitative graphs are mean +/- SEM from at 
least three independent experiments.  
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ABT263 eliminates senescent tumor cells in-vitro.  
To evaluate the senolytic effect of ABT-263, MDA-MB-231 cells were first induced into 
senescence and then exposed to ABT263. ABT263 (2 µM) effectively eliminated SA-β-
gal-positive cells (Figure 9A). Significantly increased apoptosis was observed in the 
ABT263 treated senescent population, as detected by increased annexin V-positive 
cells (Figure 9B) and upregulated apoptosis markers  cleaved PARP and cleaved 
caspase 3. (Figure 9C) 
ABT263 is selective for senescent cells as it did not show significant toxicity against 
untreated tumor cells (Figure 10A) when compared to senescent MDA-MB-231 that were 
in a state of prolonged growth arrest over a period of time following exposure to either 
Dox ((0.75 µM)) or radiation (8Gy) (Figure 10B).  
These results confirm the senolytic potential of ABT263 in vitro and shows its ability to 
effectively eliminate a residual population of cells that did not succumb to the cytotoxic 
action of either doxorubicin or radiation alone. 
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Figure 9.  Elimination of senescent cells after exposure to doxorubicin or 
radiation by ABT263. A and B. ABT-263 induces apoptotic cell death in senescent 
cells. B. Annexin V/PI quantification of apoptosis induced by ABT-263 in MDA-MB-
231 cells after treatment with doxorubicin/etoposide (upper panel) or irradiation 
(lower panel). C. Western blotting for cleaved PARP and cleaved caspase-3 in 
MDA-MD-231. All images are representative fields or blots from at least three 
independent experiments, and all quantitative graphs are mean +/- SEM from at 
least three independent experiments.  
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Figure 10. Selective elimination of senescent breast tumor cells by ABT263. A. Time 
course of cell viability after 48 hours exposure to ABT 263 (2 µM). B. Effects of ABT 263 on 
cells induced into senescence by doxorubicin or radiation. Viable cell number assessed  by 
trypan blue exclusion method at indicated time points. 
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ABT263 induces enhanced apoptosis in tumors following doxorubicin treatment 
in-vivo.  
As the goal of our studies is to develop a sequential treatment strategy that could be 
clinically relevant, we investigated whether ABT263 exerts its senolytic effects in tumor 
bearing animals. For this study, female NSG mice were challenged with MDA-MB-231 
tumor cells. After measurable tumors formed, animals were treated with doxorubicin (2.5 
mg/kg total of three injection) in order to induce senescence in-vivo.  We determined that 
tumor cells undergo senescence as a result of exposure to chemotherapy, as we were 
able to detect considerably elevated expression of SA-β-gal in tissue samples collected 
from mice that received chemotherapy (Figure 11 Left Panel). We were also able to 
confirm that senolytic potential of ABT263 observed in culture can be translated to in-vivo 
studies as well. Tumor tissue collected from animals treated with doxorubicin showed 
elevated levels of cleaved PARP as chemotherapy alone induces some cell death in the 
tumors. Cleaved PARP staining, however, was much more prominent in samples 
collected from animals that received doxorubicin followed by ABT263, which animals 
received at a concentration of 100 mg/kg by oral gavage in total of six administrations 
(Figure 11 Right Panel). Collectively these observations suggest that ABT263 can be 
used to effectively target senescent cells. The ability of ABT263 to induce robust 
apoptosis in tumors after induction of senescence in-vivo further suggests that sequential 
treatment that includes chemotherapy followed by a senolytic agent shows promise in 
terms of clinical relevance.    
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D. Discussion 
Senescence still remains a desirable outcome of treatment, which is logical considering 
that it can provide patients with a progression-free state of disease for a prolong period 
of time. Also, senescent cells can be subject to immunosurveillance and elimination by 
cytotoxic lymphocytes, which is an additional benefit to successful therapy.  
However, senescence as a response to therapy can have quite negative outcomes. 
Observations made during our studies, consistent with results obtained in other 
laboratories, indicate that senescent growth arrest may not be permanent. In fact, 
Therapy Induces Senescence appears to be reversible[92], [93] .  Senescent cells are 
not only able to escape arrest, but they have been shown to give rise to highly 
aggressive therapy resistant populations. [93] 
Figure 11. In vivo induction of senescence by doxorubicin and elimination of the  
senescent cell population by ABT263. Left panel. SA-b-Gal staining in tumor tissue 
resected from animals that received 3 injections of 2.5 mg/kg doxorubicin ± ABT-263 
(100 mg/kg daily for 2 days). Right panel. Cleaved PARP in tissue of tumors resected 
from animals that received doxorubicin ± ABT-263.          
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Another feature of senescent cells that can be quite deleterious is their inflammatory 
profile. Many models of aging are based on the observation that senescent cells 
accumulate in the body causing disease and frailty.  Some studies also show that 
senescence as a side effect of therapy can cause secondary disease such as heart 
failure. [94]  SASP has been termed “The dark side of senescence” because of its ability 
to promote chronic inflammation and tumorigenesis. Cytokines IL-6 and IL8, two of the 
most prominent components of SASP are known to activate pathways such JAK/STAT3 
[95], which is responsible for pro-tumorigenic paracrine stimulation of tissue that is 
adjacent to tumors, stimulate metastatic progression and suppress immune responses. 
Despite negative features of senescence, we can still consider it a desirable outcome if 
senescent cells can be perceived as targets for elimination. A plethora of studies have 
been performed to explain how senescent cells are able to evade apoptosis. As a result, 
anti-apoptotic properties of those cells are well described. For example, it is known that 
upregulation of anti-apoptotic proteins of the BCL-2 family is one of the hallmarks of 
senescence. Utilizing existing knowledge, we chose to target those proteins by using 
ABT263 (BCL-2 and BCL-XL inhibitor).  Our studies confirm that ABT263 exerts minimal 
toxicity against untreated tumor cells. However, it is quite effective at clearance of cells 
induced into senescence by therapies. Our studies also show that  this agent is able to 
induce elevated levels of apoptosis in tumors in-vivo, making sequential treatment 
promising in terms of residual tumor elimination without added toxicity.               
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E. Future Directions 
During studies In our laboratory we identified some cell lines that are resistant to 
ABT263 as a senolytic (Figure 12A), although they readily undergo senescence.  
Evidence in the literature suggest, that responses to ABT263 can differ depending on 
the cell line.  Results obtained in 4T1 mouse model of Triple Negative Breast Cancer 
showed these cells to be insensitive to Navitoclax.  Several hypothesis can explain lack 
of senolytic effect in cases of 4T1 cell line. One explanation is that these cells do not 
overexpress BCL-2 proteins when senescent, or overexpress MCL-1 antiapoptotic 
protein, which can rescue them from cell death induced by BCL-2/ BCL-XL  inhibitor 
(ABT263). The mechanism behind this resistance has to be elucidated as senolytic 
agents shows promise in the clinic. Alternative way to eliminate senescent cells is by 
exposing them to the Histone Deacetylase (HDAC) inhibitor Panobinostat (Pano). 
Histone deacetylase (HDAC)  enzyme that removes acetyl group from histone lysine 
residue, thus regulating gene expression.  This drug is clinically approved for treatment 
of Multiple Myeloma [96]  and is also in trials for lung cancer [97].   
Panobinostat  was proven to eliminate senescent lung tumor cells [98], but it has yet to 
be tried in other types of cancer. We performed preliminary studies with Panobinostat 
and found that 48 hours exposure to 50 nM concentration resulted in temporary growth 
arrest in non-treated cells (Figure 12 B), observation that is consistent with studies that 
show  Pano induced G2 arrest. [99] 
  Notably,  cells induced into senescence by either doxorubicin or paclitaxel  were 
effectively eliminated (Figure 12 C, E) through induction of apoptosis (Figure 12D) 
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Pano  was efficacious in combination with taxol in Non-Small Cell Lung Cancer in the 
studies that show its ability to reduce BCL-XL  expression [97]. 
However, because experiments with ABT263 in 4T1  did not lead to elimination of 
residual cells following chemotherapy we think that BCL-XL might not be consequential 
in senescent 4T1 survival .  Senolytic action of Panobinostat in 4T1 may have a 
different mechanism. One possibility that Pano may reduce expression of other anti-
apoptotic proteins like MCL-1 or regulate increase in pro-apoptotic ones. 
 Studies also showed that senescent cells undergo aberrant mitosis which can be a 
mechanism of cell death [64] For example, mitotic catastrophe was noted as one such 
mechanism. [64] As Pano was implicated in causing mitotic defects it’s action could be 
induction of apoptosis through abbearnt cell division.     
Because Panobinostat is can broadly direct gene expression, additional mechanistic 
studies are needed in oreder to explain it’ s senolytic potential in cell lines resistant to 
BCL-2 family inhibitors.   
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Figure 12. Senolytic effects of Panobinostat on ABT 263 resistant 4T1 cells. 
A. Time course of cell viability after 48 hours exposure to 2 µM  50 ABT 263. 4T1  
cells were induced into senescence by 2 hours exposure to Dox. Non-treated 
controls and Dox treated cells were exposed to ABT263. Number of viable cells 
was determined by trypan blue exclusion method at indicated time points. B. 
Effect of Panobinostat given at 50 nM for 48 hours on  4T1 cells induced. C. 
Clearance of cells  into senescence by doxorubicin. Two days after chemotherapy 
exposure, cells were treated with Panobinostat and number of viable cells was 
assessed  by trypan blue exclusion method at indicated time points. D. 
Quantification of apoptosis 4 days after chemotherapy exposure.  Panobinostat  
was added at day 3 and kept overnight. E. Growth curve of cells treated with 
Paclitaxel for 24 hours followed by 48 hours exposure to Panobinostat 2 days after 
chemotherapy removal.       
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A. Introduction 
 
Even after an initially successful therapy, triple negative breast cancer (TNBC) patients 
often relapse with therapy resistant disease, because of incomplete elimination of the 
tumor [100]. Although efforts to mobilize the immune system have resulted in beneficial 
outcomes for melanoma and lung cancers, it has not yet proven to be widely successful 
in the treatment of breast cancer [101]. TNBC cells are not highly immunogenic 
because this form of the disease downregulates tumor specific antigens and amplifies 
immune suppressor cell populations. One approach to improve the immunogenicity of 
TNBC, which we have reported previously, is to inhibit the chromatin-remodeling 
complex NURF [55]. Since immune therapy is unlikely to be used as a stand-alone 
approach, we investigated whether NURF inhibition can sensitize TNBC cells to 
standard of care therapies and further enhance immune recognition, with the intent of 
eliminating the tumor cell population.  
Cytotoxic therapies exert cell autonomous effects on tumor cells that often involve DNA 
damage, resulting in apoptosis, senescence and/or autophagy [102] [103].  Those 
processes can be accompanied by cell non-autonomous effects including the release of 
damage associated molecular patterns (DAMPs) [104] and cytokines/chemokines that 
can influence the antitumor immune response. The immune response serves several 
functions, including recognition and elimination of tumor cells, while also promoting a 
tumor antigen specific response [105] which can eliminate residual cancer cells, 
potentially resulting in long-term disease remission.  
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Therapy induced DNA damage upregulates cell surface ligands that activate immune 
cells. In particular, the DNA damage response leads to ATM/ATR activation-dependent 
upregulation of NKG2D and DNAM1 ligands on the surface of tumor cells [93].  These 
ligands bind to the NKG2D or DNAM1 receptors respectively on Natural Killer (NK) or T 
cells, which are prominent components of the antitumor immune response. NK and T 
cells in turn recognize and eliminate tumor cells undergoing therapy induced DNA 
damage or stress [106].  For instance, in established models of liver fibrosis, NK cells 
are proven to eliminate senescent hepatic cells, preventing disease progression playing 
a crucial role in the antitumor immune response [107].   
Cytotoxic therapies are also known to induce autophagy, which as discussed prior, can 
be a contributing factor to tumor cell elimination by the immune system. 
The epigenetic modulator, NURF, is an ATP dependent chromosome-remodeling factor 
that regulates gene expression by sliding DNA into chromatin [108]. It is composed of at 
least three subunits including the largest and essential bromodomain PHD-finger 
containing transcription factor (BPTF), the ATPase SNF2L and the WD repeat protein 
pRbAp46/48 [55]. Genetic or pharmacologic inhibition of BPTF results in the selective 
inhibition of NURF because it is essential for the function of the complex [109].  BPTF is 
necessary for embryonic development and particularly was found to be necessary for 
mammary gland development. However, NURF has also been implicated in driving 
cancers through regulating Myc [110]. Given that NURF has been shown in several 
models of breast and melanoma cancers to suppress the antitumor immune response by 
reducing tumor immunogenicity [56],[57] as an epigenome regulator, BPTF is potentially 
a druggable target that can be exploited for therapeutic benefit.  
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Small molecule GSK1379725A  or AU1 which showed to be selective for BPTF is the 
only pharmacologic inhibitor characterizes this far  [111].  AU1 binds to the BPTF and 
inhibits its ability to  attach to the DNA. As a result, the whole NURF complex is 
prevented form binding DNA.  When tested in hepatocytes at 10 µM concentration, AU1 
did not show significant cytotoxicity.   [112]. Similar results were obtained when 
HEK293T were exposed to the drug. We used 10 µM concentration for 48 hours to 
ensure effective BPTF inhibition without significantly toxic side effects.   
The main objectives of this work were to achieve enhanced response of tumor cells to 
chemotherapy by depletion of NURF.  We wanted to investigate if NURF inhibition can 
potentiate effects of therapy in tumor bearing animals and whether response is immune 
system mediated.  Also, we wanted to determine if  autophagy is a mechanism  by 
which anti-tumor immune response is activated and is necessary for the optimal 
outcome of anti-cancer treatment.         
In our studies we were able to show that BPTF depletion by shRNA leads to increased 
DNA damage resulting after treatment with Doxorubicin. In addition, BPTF KD cells 
show significantly elevated autophagy resulting from exposure to the Topoisomerase II 
poisons doxorubicin and etoposide. BPTF KD cells treated with chemotherapy were 
found to be a target of robust elimination by immune cells particularly NK cells due to 
changes in the secretome that leads to  NK cell activation.  
In-vitro experiments in which BPTF was inhibited pharmacologically by administration of 
AU1 recapitulated effects of genetic knock down. 4T1 cells treated with AU1 in 
combination with Doxorubicin showed increased sensitivity to chemotherapy  and 
elevated autophagy.   
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B. Materials and methods 
 
Cell Culture. Scrambled shRNA  (WT) and shBPTF  (BPTF KD)  (described in  [63]) 
4T1 (Gift from Fred Miller, Wayne State University), MDA-MB-231 (ATCC, Cat# HTB-
26™) and HEK 293T (ATCC, Cat# CRL-3216) were  maintained in DMEM 
supplemented with 10% fetal bovine serum (Thermo Scientific, SH30066.03) 100 U/ml 
penicillin G sodium (Invitrogen, 15140–122), and 100 μg/ml streptomycin sulfate 
(Invitrogen, 15140–122) at 37º C and 5% CO2. 
The ATG5-knocked down variants were generated as follows: mission shRNA bacterial 
stocks for ATG5 were purchased from Sigma-Aldrich (TRCN00151963) and lentivirus 
generation was conducted in the HEK 293TN cells. Co-transfection was performed using 
lipofectamine (Invitrogen, 11668–019) with a packaging mixture of psPAX2 and pMD2.G 
constructs (Addgene, 12260, 12259). After 48 h, viruses shed into the media were 
collected and used to infect cells under ultrasonic centrifugation for 2 hours. Selection 
was performed in puromycin (Sigma-Aldrich, P8833) (1-2 μg/ml).  
 
Drugs and Radiation. Chemotherapies used were obtained from the Massy Cancer 
Center hospital pharmacy or Millipore-Sigma and include gemcitabine (Cat# G6423), 5-
flurouracil (Cat#F6627) doxorubicin (Cat# D1515), paclitaxel (Cat# T7402), cisplatin 
(Cat# BP809) azacytidine (Cat# A2385) or panobinostat (LC Laboratories).  Radiation 
dosing was performed using a 137Cs irradiator. 
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Clonogenic Survival Assays. In the evening, cells were dispersed from culture using 
trypsin to generate single cells, diluted and then plated at 400 cells/well of a 6 well plate 
in 2 ml of media. The following morning ,cells were treated with chemotherapy or 
radiation. Cells were treated for 24 hrs. after which they were washed and cultured in 2 
ml of fresh media. Cells were cultured until colonies in untreated cultures were clearly 
visible. Colonies were stained with crystal violet (0.05% crystal violet, 1% formaldehyde, 
1% methanol, PBS) and counted. The fraction viable after treatment was calculated by 
the ratio # colonies treated / # colonies untreated. 
Topoisomerase II  Measurement 
Top2ccs were isolated and detected using in vivo complex of enzyme (ICE) assay as 
previously described (Anand et al., 2018). Briefly, cells were lysed in sarkosyl solution 
(1% w/v) after treatment. Cell lysates were sheared through a 25g 5/8 needle (10 
strokes) to reduce the viscosity of DNA and layered onto CsCl solution (150% w/v), 
followed by centrifugation in NVT 65.2 rotor (Beckman coulter) at 42,000 RPM for 20 
hours at 25 °C. The resulting pellet containing nucleic acids and TOP2ccs was obtained 
and dissolved in TE buffer. 2 μg of DNA is applied per slot on the blotting apparatus. 
The DNA in the sample was quantitated by NanoDrop™ 2000 spectrophotometer and 2 
μg of DNA is applied per slot on the blotting apparatus. The slot-blot membrane was 
subsequently subjected to immunoblotting with Top2 alpha (Abcam, Cat# ab52934) and 
Top2 beta (Novus Biologicals, Cat# NB-100-40842) antibodies. Blots were incubated 
with the primary antibodies over night at 4°C and then subjected to 1:10,000 anti-mouse 
or rabbit HRP secondary antibody (GE Healthcare, Cat# NA931 and Cat# NA934) 
incubation for 1 hour at room temperature. Quantitative slot blotting was performed 
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using Pierce Super Signal ELC Femto detection reagent (Thermo Fisher, Cat# 37075 
with the Bio-Rad ChemiDoc® System. Top2cc signals were quantified by densitometric 
analysis using ImageJ. 
 Determination of DNA damage. 
Cells were treated with Doxorubicin (50 nM), Etoposide (300 nM) and Paclitaxel (50 
nM) for 24 hours. After drug removal cells were collected, washed with PBS and 
centrifuged. Pellets were resuspended in 70% ice cold Ethanol fixed and permeabilized 
for 30 min at RT. Then cells were washed in PBS again, resuspended in 5% BSA and 
blocked for 30 min on shaker. gH2AX conjugated antibody (BD Pharmigen, 
Cat#560445) was added 1:100 and cells were stained for 1.5 hours on shaker 
protected from light.    
 
Western Blotting. 
Total proteins from cell cultures were extracted by TRI Reagent (Millipore-Sigma, Cat# 
T9424) using manufactures suggested protocol. Protein pellets were dissolved in 8M 
urea and 1% SDS at 65 C then quantified using the DC protein assay (BioRad, Cat# 
5000112) and a BSA standard. Proteins were resolved by SDS-PAGE, transferred to 
PVDF using a submersible system with 10 mM N-cyclohexyl-3-aminopropanesulfonic 
acid (CAPS), pH 10.5 at 20 mV, 20 mA and overnight. Membranes were blocked and 
probed using 5% nonfat milk in PBST. Primary antibodies: 1:1000 anti-BPTF (Millipore-
Sigma, Cat# ABE24), 1:1000 anti-SNF2L , 1:1000 pRbAp46/48 , Top2 alpha (Abcam, 
Cat# ab52934), Top2 beta (Novus Biologicals, Cat# NB-100-40842), 1:10,000 anti-
Cyclophilin B (Thermo Fisher, Cat# PA1-027A), 1:1,000 anti-GAPDH (Cell Signaling, 
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Cat# 2118), then 1:10,000 anti-mouse or rabbit HRP secondary . Quantitative Western 
blotting was performed using Pierce Super Signal ELC Femto detection reagent 
(Thermo Fisher, Cat# 37075) with the LI-COR Odyssey® Fc system. Loading was 
determined by Cyclophilin B or GAPDH. 
 
Visualizing and quantification of acidic vesicles with acridine orange staining. 
Cells were seeded in 6-well plates and allowed to adhere overnight. After exposure to 
chemotherapy or radiation, cells were stained with 1 μg/ml acridine orange at 37℃ for 
25 min and then washed with PBS. Cells were observed under an inverted 
fluorescence microscope (Olympus, Tokyo, Japan) and images taken at 20X 
magnification. For quantification of autophagy, cells were collected with trypsin and 
washed with PBS. Pellets were resuspended in PBS and analyzed by BD FACS Canto 
II and BD FACS Diva software. All experimental procedures were performed with cells 
protected from light. 
β-galactosidase and C12FDG staining. To quantify b-Gal positive senescent cells, 
after exposure to Doxorubicin, cells were treated with Bafilomycin (100 nM) for 1 h to 
achieve lysosomal alkalinization (needed in order to detect lysosomal  b-Gal only) and 
stained with C12FDG (10 μM) fluorescent b-Galactosidase substrate for 2 h at 37 oC. 
After incubation, cells were collected, washed, resuspended in PBS and analyzed by 
flow cytometry. All experimental procedures were performed with cells protected from 
light. 
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Determination of cell apoptosis.  Apoptosis was monitored by Annexin V-FITC/PI 
staining (AnnexinV-FITC apoptosis detection kit, BD Biosciences, 556547) according 
to the manufacturer’s instructions. Samples were analyzed by BD FACSCanto II and 
BD FACSDiva software at Virginia Commonwealth University Flow Cytometry Core 
Facility as described previously. 
NK Cell Cytotoxicity Assay. NK cells were purified from the spleen of naïve BALB/c 
mice by negative selection using magnetic column MACS separation (Miltenyi Biotech). 
NK cells were assayed in low LDH media (DMEM, 10% heat inactivated FBS, 1% NEAA, 
2mM glutamine, and 1% penicillin/streptomycin) supplemented with 50 U/ml mouse IL-2 
(Thermo Fisher, Cat# RP-8605). For direct killing measurements purified mouse NK cells 
were placed on control or doxorubicin targets for 24 hrs. For media preconditioning, 4T1 
cells were treated with 50 nM doxorubicin for 48 hrs. followed by 48 hrs. of recovery in 
fresh CM media, growth media was then removed and incubated with NK cells for 24 hrs 
before assay on targets. Cell death of targets was measured using the Pierce LDH 
Cytotoxicity Assay Kit (Thermo Fisher, Cat# PI88953).  
Tumor Studies. BALB/cJ female mice 6-8 weeks of age weighting ~ 20 g (Jackson 
Laboratory) were housed under aseptic barrier conditions as approved by Virginia 
Commonwealth University IACUC animal protocol AD10000017. 5x10^4 4T1 cells were 
surgically transplanted into the fourth mammary fat pad. Tumors were measured by 
caliper measurements 3 days/week starting from day 7 post transplantation. Doxorubicin 
was given intraperitoneally (i.p)  at 5mg/kg doses  at days 5, 22 and 29 and were provided 
nutrient to maintain weight.  
 60 
mAb Depletions. SH-34 mAb depletions were performed as described previously [Ref]. 
Briefly, mAbs were purified from hybridoma clone SH-34 (ATCC, Cat# CRL-2405) ascites 
fluid by ammonium sulfate fractionation as approved by Virginia Commonwealth 
University IACUC animal protocol AD10009079. Purified antibodies were injected i.p. at 
225 µg/mouse on day -2, and -1 prior to tumor cell transplantation. Tumors were 
inoculated on day 0 and mAb was injected once every 5 days following tumor inoculation. 
Creating ATG5 
 
C. Results 
 
NURF inhibition sensitizes breast tumor cells to select chemotherapeutic agents. 
We employed a BPTF knock down (KD) (Figure 13A) to assess the effect of NURF 
inhibition on sensitivity of breast tumor cells to anti-cancer drugs.  4T1 mouse mammary 
tumor cells were exposed to the chemotherapeutic drugs commonly used in the 
treatment of breast cancer as well as to ionizing radiation. In clonogenic survival 
assays, the BPTF KD cells were shown to be sensitized to doxorubicin (Dox), etoposide 
(Eto) and paclitaxel (Pac) but failed to demonstrate enhanced sensitivity to ionizing 
radiation. (Figure 13B). Significant decreases in colony formation were observed with 
doxorubicin and paclitaxel, which suggests that BPTF KD can sensitize tumor cells to 
therapies with different mechanism of action [119].  BPTF knock down also sensitizes 
human Triple Negative Breast Cancer cells MDA-MB-231 to Dox (Figure 13C). Mouse 
embryonic stem cells C7J were not sensitized to chemotherapies (Figure 13D), 
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suggesting that BPTF sensitization associated with BPTF depletion is selective for 
cancer cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Sensitization of NURF KD cell lines to anti-tumor modalities.  A. Western 
Blot confirming BPTF knock down in 4T1 mouse mammary tumor cells. B. Clonogenic 
survival of BPTF WT and BPTF KD cells after exposure to indicated modes of therapy. 
C.  Impaired colony forming ability due to BPTF depletion in MDA-MB-231 human breast 
cancer cell line treated with doxorubicin. D. Lack of enhanced sensitization to doxorubicin 
in C7J mouse embryonic fibroblast cells        
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NURF inhibition enhances doxorubicin and etoposide induced DNA damage.  
Doxorubicin and etoposide are both DNA damaging agents that interfere with 
topoisomerase II activity, resulting in the generation of double stranded breaks [113] 
[114]. Consequently, it appeared possible that the sensitization of BPTF KD cell to 
these drugs could be mediated, at least in part, through an increase in DNA damage. As 
there is evidence that paclitaxel is also capable of inducing DNA damage [115], this 
appeared to be a possibility that would extend to all three drugs.   The extent of DNA 
damage incurred in response to doxorubicin, etoposide, paclitaxel and radiation 
treatment was determined by quantifying 𝛄H2AX foci (indicative of DNA damage) 
formation 24 hours after drug exposure (Figure 14A). Flow cytometry quantification 
indicated that more DNA damage foci were generated in BPTF KD cells following 
doxorubicin and etoposide exposure than in the cells expressing a scrambled shRNA . 
In contrast, paclitaxel induced low and essentially similar levels of DNA damage (H2AX 
positive cells) in both shControl (WT) and shBPTF (KD) cells, indicating that 
sensitization to paclitaxel was likely to be a consequence of other mechanisms. As 
might have been anticipated from the lack of enhanced sensitivity to radiation in the 
BPTF KD cells using clonogenic survival (Figure 13B ), enhanced therapy induced 
DNA damage to BPTF KD cells was not observed with radiation treatment (Figure 
14A). 
As it appeared quite clearly that BPTF KD cells are particularly sensitive to 
Topoisomerase II poisons, we therefore decided to investigate whether TOPOII is 
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recruited to the DNA of treated BPTF KD at a higher rate compared to WT 4T1. When 
nuclear fractions of cells were obtained and DNA pulled down and analyzed, high 
accumulation of both types of TOPOII: Topcc alfa and Topcc beta was observed. 
Because doxorubicin and etoposide induce DNA damage by targeting TOPOII these 
drugs are able to  induce higher DNA damage if there are more TOPOII associated with 
DNA strands, making more targets available. High levels of TOPO II associated with DNA 
in BPTF KD cells can be due to two factors: BPTF suppresses transcription of TOPOII, 
and when BPTF is depleted more TOPOII protein is actually synthesized. However, BPTF 
KD cells did not show increased recruitment of TOPOII to the DNA in absence of 
chemotherapy (Figure 14B) The other possibility  is  that BPTF and TOPOII bind in the 
same regions of DNA, if BPTF is upregulated it obscures DNA from TOPOII, whereas  
BPTF depletion allows for expansion of binding cites and  TOPOII is able to bind DNA 
more efficiently. Our data supports the latter hypothesis.      
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Figure 14. Increased DNA damage in NURF KD cells in response to 
topoisomerase II poisons.  A. Extent of DNA damage was determined by Flow 
Cytometry using H2AX fluorescent marker. B.  Recruitment of TOP2cc alpha and 
TOP2CC beta to the DNA.  C. Quantitative Western Blot analysis of TOP2cc Alpha of 
BPTF WT and BPTF KD cells treated with etoposide and doxorubicin. D. Quantitative 
Western blot of Top2cc beta in BPTF WT and BPTF KD after exposure to 
chemotherapy       
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NURF inhibition increases doxorubicin and etoposide induced autophagy and 
paclitaxel induced apoptosis. 
The promotion of DNA damage in tumor cells may lead to growth arrest or cell death.  We 
therefore examined three potential responses to the treatments with doxorubicin, 
paclitaxel and etoposide, specifically apoptosis, senescence and autophagy. Exposure to 
doxorubicin, etoposide or paclitaxel promoted apoptosis in shControl (WT) as well as 
BPTF KD cells as shown in Figure 15. In the case of etoposide and paclitaxel, apoptosis 
was higher in the BPTF KD cells; however, doxorubicin induced moderate apoptosis in 
4T1 cells (approximately 20% of the cell population), with no difference between WT and 
BPTF KD cells (Figure 15). Consequently, despite the fact that sensitization was evident 
for all three drugs, it is clear that they are likely to be distinct in the mechanistic basis for 
the sensitization.  
 
 
 
Figure 15. Increased apoptosis in NURF KD cells in response to etoposide and 
paclitaxel. Cells were exposed to Eto (300 nM), Pac (50 nM) and Dox (50nM) for 48 
hours. After treatment removal, cells were washed with PBS and allowed to recover in 
fresh media. Cells were collected 24 hours after drug removal and percent of apoptotic 
cell was determined by Flow Cytometry 
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 Previous work by our laboratory has identified senescence as primary response to 
chemotherapy (and radiation) in various tumor cell models [116] [117] Induction of 
senescence was confirmed first by microscopy, showing increased SA-β-galactosidase 
staining (Figure 16A). Doxorubicin, etoposide and paclitaxel promoted an equivalent 
extent of senescence in WT and BPTF KD cells. Quantification by Flow Cytometry 
based on SA-β-galactosidase expression. 
 demonstrated that approximately 60% of the cell population was senescent after 
exposure to doxorubicin, 50% after etoposide treatment and between 30% and 40% 
senescence was induced with paclitaxel. (Figure 16B).  However, the overall extent of 
senescence was indistinguishable between BPTF WT and BPTF KD cells.  
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Figure 16. Senescence in BPTF WT and BPTF KD 4T1 A. Increased SA-β-gal 
activity determined by electron microscopy using x-Gal staining. B. Quantification of 
senescent cells by flow cytometry using C12FDG fluorescent SA-β-gal substrate.  
Analysis was performed 48 hours after drug removal. 
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Figure 17. Doxorubicin and Etoposide induce robust autophagy in 4T1 breast 
tumor cells. Images of autophagic cells obtained by fluorescent microscopy using 
Acridine Orange fluorescent dye.  
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 We have previously reported on the collateral induction of autophagy and senescence 
in response to doxorubicin [118]. Autophagy is, in fact, a relatively consistent response 
of tumor cells to chemotherapy and radiation [126]. Autophagy was considerably 
enhanced in the BPTF KD cells compared to controls upon treatment with doxorubicin 
and etoposide (Figure 17). When quantified by Flow Cytometry autophagy showed to 
be significantly enhanced in BPTF KD cells treated with Dox or etoposide (Figure 18). 
Exposure to ionizing radiation resulted in very modest autophagy induction that did not 
differ between BPTF WT and KD cells (Figure 18). Paclitaxel did not induce autophagy 
in either WT or BPTF KD cells (Figure 18), again consistent with the premise that 
sensitization to paclitaxel is occurring by different mechanism(s) than for doxorubicin 
and etoposide. 
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Figure 18.  Percent of autophagy is increased in BPTF KD 4T1 cells in response to 
topoisomerase poisons doxorubicin and etoposide. Flow cytometric quantification of 
autophagic cells  based on Acridine Orange dye following indicated treatments.    
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NURF inhibition enhances breast tumor cell sensitivity to doxorubicin in vivo. 
To investigate whether BPTF KD might also contribute to in vivo sensitization of tumors 
to chemotherapy, mice were orthotopically implanted with both WT and BPTF KD 4T1 
breast tumor cells. In the absence of drug treatment, growth rate of BPTF WT and BPTF 
KD was not significantly different, slight decrease in BPTF KD tumor growth can be 
associated with the fact that BPTF KD tumor cells can be subject to some immune 
surveillance. (Fig 19 Upper Panel). However, after doxorubicin treatment, BPTF KD 
tumors showed reduced rates of tumor growth compared to similarly treated WT tumors 
(Fig 19 Lower Panel).  
 
NURF inhibition results in enhanced NK cell cytotoxic activity to chemotherapy 
treated breast tumor cells.  
It was previously shown that NURF inhibition enhances NK cell antitumor activity to breast 
tumors. To determine if these effects are further improved in the context of chemotherapy, 
we investigated whether chemotherapy treated BPTF KD cells present a better target for 
Natural Killer cells. For this study, 4T1 WT and BPTF KD were exposed to 
chemotherapies for 48 hours then allowed to recover in drug-free media for another 48  
hours. After recovery, 4T1 cells were co-cultured with NK cells isolated from syngeneic 
BALB/C mouse spleen. 24-hour co-culture period was followed by analysis of cell lysis 
and LDH release. Treatment with doxorubicin resulted in significant increase of NK cell 
cytotoxic activity to BPTF KD cells (Figure 20). This observation leads us to believe that 
either membrane-bound or secreted factor stimulates NK cell cytotoxic activity to Dox 
treated BPTF KD 4T1.  
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Figure 19. In-vivo growth of BPTF WT and BPTF KD 4T1 with and without doxorubicin 
treatment.  Mice (n=8) were challenged with BPTF WT and BPTF KD tumor cells (50X104). When 
palpable tumors appeared, animals received one i.p. injection of 5 mg/kg doxorubicin per week for 
3 weeks.   Caliper measurements of tumors were taken every other day.  
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 There is an established paradigm connecting DNA damage in tumor cells and increased 
cytotoxic activity of NK cells [119] [120].  Among factors that are upregulated in 
response to DNA damage and are known to activate antitumor NK cell activity are 
NKG2D ligands. NKG2D are NK cell activating receptors that bind corresponding cell 
surface proteins cell surface proteins [121] . BPTF WT and BPTF depleted cells treated 
with doxorubicin show increased levels of NKG2D ligands as was determined by flow 
cytometry after staining with an NKG2D-Fc  (Figure 21E, 21F ). However, the increase 
Figure 20. Enhanced NK cell activity against doxorubicin treated BPTF KD cells. NK cells 
were isolated from the splenocytes of BALB/c mouse by magnetic separation method and co-
cultured for 24 hours   with BPTF WT and BPTF KD 4T1 that were treated with doxorubicin or 
received no drug at 5:1 effector/target ratio. Cytotoxic potential of the NK cells was determined 
by LDH assay.  
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in membrane bound NKG2D ligands are not significantly different between BPTF WT 
and BPTF KD cells.  
 
 Other factors that can contribute to the sensitivity of tumor cells for recognition 
and elimination by cytotoxic lymphocytes, including NK cells (are the DAMP cell surface 
Heat shock protein (cmHsp70) [122], [123] and Calreticulin [132] (Figure 21A, 21B). 
CmHsp70 may facilitate the process by escorting granzyme B into the interior of the 
tumor cell. While we observed significant upregulation of cmHSP70 in response to 
doxorubicin treatment, levels of Hsp70 were similar between WT and BPTF KD 4T1 
cells (Figure 21C, 21D). Taken together, this series of experiments indicates that 
membrane bound markers of cellular stress that can promote recognition of the injured 
tumor cells by the NK cells are elevated in doxorubicin- treated 4T1 cells, but not 
apparently different in WT and BPTF KD cells.  
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Figure 21. Expression of DAMP factors on the membrane of doxorubicin treated WT 
and NURF KD 4T1 cells: A, B. Determination of Calreticulin exposure on the cell surface 
by Flow Cytometry C, D. Flow Cytometric analysis of Heat Shock Protein 70, HSP70. 
Analysis E, F. analysis of NKG2D ligands on the surface of BPTF WT and BPTF KD cells 
by Flow Cytometry  
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An alternative possibility was that a secreted factor (such as cytokines/chemokines) might 
stimulate NK cell cytotoxic activity to BPTF KD tumor target cells. To address this 
question, we show in Figure 22 that NK cells exposed to the media collected from 
doxorubicin-treated BPTF KD were capable of killing naïve 4T1 tumor cells at significantly 
higher rates than NK cells exposed to the media from doxorubicin-treated WT cells 
(Figure 22 ). These results suggest the presence of an NK stimulating soluble factor that 
contributes to the immune system response as a component of the cell non-autonomous 
effect of doxorubicin treatment. 
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Figure 22. Conditioned media collected from doxorubicin treated NURF KD cells 
increases cytotoxic activity of NK cells. BPTF WT and BPTF KD cells were treated with 
doxorubicin for 48 hours and allowed to recover in fresh media for another 48 hours. Then, 
media was collected and used to incubate NK cells for 24 hours. NK cells were isolated from 
the splenocytes of BALB/c mouse by magnetic separation method and incubated in the 
conditioned media obtained as described and supplemented with IL-2. After pre-conditioning 
period NK cells were co-cultured with naïve 4T1 targets at 5:1 effector/target ratio. Cytotoxic 
potential of the NK cells was determined by LDH assay. 
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Immuno-sensitizing effects of NURF knock down rely on NK cell mediated 
antitumor activity and autophagy in preclinical mouse tumor models.  
We investigated if reduced tumor growth in doxorubicin-treated animals challenged with 
BPTF KD tumors in fact relies on activated NK cells. As shown in Figure 23, NK cell 
depletion by monoclonal antibody leads to the loss of the enhanced effects of doxorubicin 
in BPTF KD tumors.  
To determine if autophagy is instrumental in enhanced immune response against BPTF 
KD tumors in-vivo, autophagy deficient lines were created by knocking down Atg5 gene 
with shRNA (Figure 24A). Similarly to NK cell depletion, genetic inhibition of autophagy 
by shAtg5 leads to loss of sensitivity to chemotherapy. Animals challenged with BFTF 
control (WTshATG5) and BPTF KD (KD1Atg5KD and KD2Atg5KD)  in which autophagy 
was genetically inhibited, developed tumors at the same rate (Figure 24B).    
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Figure 23. NK cell depletion by monoclinal antibody results in loss of enhanced 
sensitivity to doxorubicin in BPTF KD tumors. In-vivo growth curve of  BPTF control 
and BPTF KD 4T1 cells in animals with NK cell depletion. Purified antibodies were injected 
i.p. at 225 µg/mouse on day -2, and -1 prior to tumor cell transplantation. After  mice (n=8) 
were challenged with tumor cells (50X104)  monoclonal antibody (mAb) against NK cells 
was injected once every 5 days. When palpable tumors appeared, animals received one 
i.p. injection of 5 mg/kg doxorubicin per week for 3 weeks. Caliper measurements of tumors 
were taken every other day.    
 
 80 
 
 
 
 
 
 
 
 
 
 
Figure 24. Genetic blockade of autophagy by shAtg5 results in loss of increased sensitivity 
to doxorubicin in BPTF KD tumors. A. Western Blot showing genetic inhibition of autophagy by 
shAtg5. B. In-vivo growth curve of autophagy competent and autophagy depleted BPTF WT and 
BPTF KD 4T1 after doxorubicin treatment.  Mice (n=8) were challenged with BPTF WT and BPTF 
KD tumor cells (50X104). When palpable tumors appeared, animals received one i.p. injection of 5 
mg/kg doxorubicin per week for 3 weeks.   Caliper measurements of tumors were taken every other 
day.  
 
    
 
A 
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Sensitization of 4T1 cells to chemotherapy using a pharmacological NURF inhibitor 
If the above findings are to have clinical significance, it will be necessary to demonstrate 
that NURF is druggable. The next series of studies demonstrate that 4T1 cells also 
demonstrate increased sensitivity to doxorubicin after NURF is blocked by a 
pharmacologic inhibitor, AU1. Figure 25A shows a pronounced reduction in colony 
formation when combining AU1 with doxorubicin. No significant decrease in colony 
numbers was observed when AU1 is combined with ionizing radiation (Figure 25B). AU1 
alone did not induce apoptosis; however, exposure of 4T1 cells to the combination of AU1 
and doxorubicin did result in increased apoptosis compared to doxorubicin alone (Figure 
25C). Although AU1 alone did not induce significant autophagy, the combination of AU1 
with doxorubicin produced a noticeable increase in the percentage of autophagic cells 
(Fig 25D). These observations suggest there is a potential synergistic effect of AU1 in 
combination with  select chemotherapies. In addition, combination of  AU1 with 
doxorubicin resulted in significantly increased senescence. Elevated levels of 
senescence and apoptosis resulting from administration of AU1 and Dox together differ 
from genetic inhibitor that could be due to of target effects of AU1. Although AU1 is 
selective for the Bromodomain of NURF complex other potential cellular targets are 
unknown.   
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Figure 25. Pharmacologic inhibition of BPTF sensitized 4T1 cells to doxorubicin 
but not radiation. 4T1 WT cells were pre-treated with 10 uM of AU1 for 48 hours then 
treated with AU1 and Dox for 48 hours, treatment was removed and cell were 
supplemented with fresh media. A. Clonogenic survival of 4T1 treated with Dox or IR 
6GY with or without AU1 B. Extent of autophagy was assessed by Flow cytometry using 
acridine orange. C. Apoptosis was quantified by flow cytometry using AnnexinV/PI 
staining. D. Percent C12FDG positive cells quantified by flow cytometry.  
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D. Discussion 
 
Our studies raise the possibility that suppression of the epigenetic modulator, NURF, has 
the potential to enhance sensitivity to chemotherapy in triple negative breast cancer 
through both cell autonomous and cell non-autonomous mechanisms. Clearly this will not 
be the case for all chemotherapeutic agents as we find this to be the case for doxorubicin 
and paclitaxel (and moderately for etoposide) but not for ionizing radiation, cisplatin or 5-
fluorouracil. The fact that the pharmacologic NURF inhibitor, AU1, also confers 
sensitization to Dox  is promising in terms of  the translational potential of these findings. 
 
Cell autonomous sensitization. From a mechanistic standpoint, we observe both cell 
autonomous and cell non-autonomous effects. One cell autonomous effect of NURF 
depletion is that of increased DNA damage in doxorubicin and etoposide treated cells (but 
interestingly, not of paclitaxel treated cells and, as would be expected, not in the case of 
radiation). These results suggest that BPTF may modulate the interaction of doxorubicin 
and etoposide with topoisomerase II, which is the basis for the promotion of DNA damage. 
A plausible explanation for this observation could be interference of BPTF with TOPO II, 
which explains high sensitivity to TOPOII inhibitors in BPTF KD cells.   
 Cell non-autonomous sensitization. Previous work has shown that BPTF depletion 
can lead to acquired immunogenicity of tumor cells by allowing expression of multiple 
proteins associated with antigen presentation by tumor cells. Our studies show that 
combining BPTF depletion and select chemotherapies, particularly doxorubicin, leads to 
more efficient recognition and elimination of tumor cells by NK lymphocytes.  Although 
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we observe increase in stress response associated cell surface markers such as 
calreticulin and HSP-70 and NKG2D ligands after treatment with doxorubicin extent of 
their upregulation was not different in BPTF WT and BPTF KD. These observations lead 
us to hypothesis  suggesting that NK cell activation is due to secreted factor, perhaps a 
component of SASP. Although the SASP is commonly associated with senescence, it is 
primarily induced by activation of DNA damage pathways and can appear prior to full 
induction of senescence [124]. In some cases, cytokine secretion occurs in response to 
ATM/ATR activation after detection of chromatin stress without noticeable DNA damage 
[125]. 
 DNA damage and subsequent ATM/ATR activation induces danger signaling by 
damaged tumor cells in response to genotoxic therapies. Damaged cells are subject to 
recognition and clearance by innate immunity mechanisms part of which is NK cells 
phagocytosis [126].    In addition to membrane bound NKG2D ligands, multiple 
cytokines are associated with activation of NK cells [127]. We observe enhanced 
activation in NK cells exposed to preconditioned media collected from BPTF KD 4T1 
treated with Doxorubicin.  NK cells exposed to conditioned media  are able to recognize 
and eliminate naïve target 4T1 cells, which means they were primed and activated by 
the molecule/molecules secreted into the media. Consistent with these observations, 
studies in tumor bearing animals show that enhanced immune response against BPTF 
KD tumors is dependent on NK cell activity as depletion of NK cells results in loss of 
increased sensitivity to Dox in animals inoculated with BPTF KD cells.  
 We were also able to confirm that enhanced autophagy is necessary for the immune 
response. Some studies indicate that autophagy can be involved in cytokine release as 
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well [128]. It has been shown that autophagy is involved in regulation of SASP [129]. 
Results of our studies clearly suggest  that autophagy regulates secretion of the NK cell 
activating soluble factor.       
 
E. Future Directions  
Most often immune function of autophagy is associated with ATP release. Studies 
performed in Dr. Landry laboratory showed no increase of ATP in BPTF KD cells after 
treatment, yet immune sensitivity of those cells is quite prominent. ATP has been 
identified as a necessary molecule to activate immune response. However, not  a lot  
of studies has been completed investigating  cytokines and chemokines release or 
autophagic degradation that can modulate immune response. It is also possible that 
autophagic degradation of metabolites that can exert inhibitory effects on NK cells 
leads to more robust cytotoxic properties of NK cells against doxorubicin treated BPTF 
KD.   
We have also determined that pharmacologic inhibitor of BPTF is effective at least in 
in-vitro studies. However, it is somewhat toxic which makes it difficult to administer 
systemically. New drugs are needed to target BPTF and other chromatin modifying 
proteins as they have been implicated in multitude of studies showing involvement of 
Epigenetic Modulators in diseases including cancer.  
 
 
 
 86 
CHAPTER FOUR 
 
Senescence and proliferative recovery are independent of non-protective 
autophagy in a model of mouse Triple Negative Breast Cancer 4T1 
Liilya Tyutyunyk-Massey, and David A. Gewirtz 
Department of Pharmacology & Toxicology (L.T.M., D.A.G.) Massey Cancer Center 
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A. Introduction 
 Both, senescence and autophagy are common responses to conventional cancer 
therapy [130],[131]. In the previous chapters we hypothesized that either autophagy or 
senescence can be  modulated in order to improve outcomes of  anti-cancer treatments. 
We showed that targeting those processes by different methods can result in enhanced 
tumor cell clearance in-vitro and in-vivo. We therefore wanted to confirm that autophagy 
and senescence can occur in parallel but be dissociated from each other.  In this chapter 
we show that senescence can be induced in cancer cells by conventional treatment 
independently form autophagy and the latter is not necessary for the survival of the 
senescent cells or their escape from growth arrest. 
Senescent tumor cells are growth-arrested and differ from regular tumor cells in 
morphology, lysosomal senescence-associated β-galactosidase expression and activity 
and are characterized by complicated secretory profile (SASP) [132]. Senescence is 
considered favorable outcome of anti-cancer treatment due to a durable growth arrest 
that is associated with it [133]. However, studies described in the Chapter 1 and in 
publication by our laboratory  suggested that the senescent growth arrest due to therapy 
is not permanent and some cells are capable of escaping senescence and  resume 
proliferation [134]. Cells that escape senescence were shown to acquire aggressive 
phenotype (135–137) and can possible contribute to the formation of refractory tumors. 
Finally, the SASP has been shown to be highly deleterious and potentially tumor 
promoting [138].  
 We have recently suggested that senescence could be one form of tumor dormancy and  
recurrence [140].  It has also been suggested that autophagy contributes to the 
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maintenance of tumors in a dormant state. In addition, autophagy can play cytoprotective 
role that allows cells escape apoptosis and can contribute to development of resistance 
to therapy. As stress responses, autophagy and senescence often  occur in parallel [141]. 
In fact, our laboratory demonstrated a linear relationship between autophagy and 
senescence induced by radiation in colon cancer cells [56]. Autophagy has been shown 
as needed component of oncogene induced senescence, which is logical as autophagy 
is a maintenance mechanism designed to protect cells from variety of damages including 
oncogenic transformation.   
In this study we show that at least in-vitro, autophagy has rather bystander effect, as it 
does not protect cells from apoptosis but also is not instrumental in either cells entering 
or escaping senescence.  
The fact that autophagy can be non-protective and thus, it does not directly influence 
outcome of therapy raises a question about whether blockade of autophagy is helpful in 
the clinical settings. Furthermore, as autophagy has been shown to be necessary for the 
immune response, use of autophagy blockers should be carefully considered.  
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B. Materials and Methods 
Cell culture and drug treatment 
4T1 cells were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum 
(Thermo Scientific, SH30066.03), 100 U/ml penicillin G sodium (Invitrogen, 15140–122), 
and 100 μg/ml streptomycin sulfate (Invitrogen, 15140–122). Cells were maintained at 
37°C under a humidified, 5% CO2 atmosphere at sub-confluent densities.  
The ATG5-knocked down variants were generated as follows: mission shRNA bacterial 
stocks for ATG5 were purchased from Sigma-Aldrich (TRCN00151963) and lentivirus 
generation was conducted in the HEK 293TN cells. Co-transfection was performed using 
lipofectamine (Invitrogen, 11668–019) with a packaging mixture of psPAX2 and pMD2.G 
constructs (Addgene, 12260, 12259). After 48 h, viruses shed into the media were 
collected and used to infect cells under ultrasonic centrifugation for 2 hours. Selection 
was performed in puromycin (Sigma-Aldrich, P8833) (1-2 μg/ml).  
4T1 cells were exposed to doxorubicin for 2 hours, washed with PBS and supplemented 
with fresh medium.  Incubation with Chloroquine (CQ 10 µM) was utilized to interfere with 
lysosomal acidification and autophagosome/lysosome fusion. Cells were treated with the 
autophagy inhibitors for 3 hours prior to the subsequent exposure to, doxorubicin or and 
the autophagy inhibitor for an additional 24 hours to ensure blockade of autophagy. All 
drugs were protected from light during handling. 
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Growth inhibition and clonogenic survival 
Growth curves were generated based on cell viability as assessed by Trypan blue 
exclusion. Cells were seeded, treated (on day 0), and counted at the indicated time points 
following the removal of the drug from the medium. For clonogenic assays cells were 
seeded, pre-treated with doxorubicin (0.25, 0.5 µM) for 2 hours, drug were then removed 
and cell provided with fresh media. Cells were incubated for 7 days, then fixed with 
methanol, stained with crystal violet, and counted (ColCount, Discovery Technology 
International). 
Analysis of senescence and autophagy by flow cytometry and microscopy 
All of the flow cytometry analyses were performed using BD FACSCanto II and BD 
FACSDiva software at the Virginia Commonwealth University Flow Cytometry Core 
Facility. For C12FDG (Life Technologies, D2893) and acridine orange analyses, 10,000 
cells per replicate within the gated region were analyzed. Three replicates for each 
condition were analyzed in each independent experiment. For β-galactosidase and 
C12FDG staining β-galactosidase labeling was performed as previously described by 
Dimri et al  and in our previous publications (). Phase contrast images were taken using 
an Olympus inverted microscope (20X objective, Q-Color3™ Olympus Camera; Olympus, 
Tokyo, Japan). The C12FDG staining protocol was adopted from (Debacq-Chainiaux et 
al). 
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Western blotting 
Western blotting was performed as previously described (16). Primary antibodies were 
used at a 1: 1000 dilution except for GAPDH (1:2000-1:8000 dilutions). Primary 
antibodies: SQSTM1/p62 (BD Biosciences, 610497), ATG5 (Cell Signaling Technology, 
2630), LC3B (Cell Signaling Technology, 3868).  
Analysis of apoptotic cell death 
Apoptosis was monitored by Annexin V-FITC/PI staining (AnnexinV-FITC apoptosis 
detection kit, BD Biosciences, 556547) according to the manufacturer’s instructions. 
Samples were analyzed by BD FACSCanto II and BD FACSDiva software at Virginia 
Commonwealth University Flow Cytometry Core Facility) and fluorescence was 
measured utilizing flow cytometry. All of the flow cytometry analyses were performed 
using BD FACSCanto II and BD FACSDiva software at the Virginia Commonwealth 
University Flow Cytometry Core Facility.  For annexin-V-FITC/ propidium iodide (PI) 
analysis, 10,000 cells per replicate within the gated region were analyzed. Three 
replicates for each condition were analyzed in each independent experiment.   
 
 
C. Results 
 
Simultaneous induction of autophagy and senescence in 4T1 cells by doxorubicin 
Figure 26 shows the collateral induction of senescence and autophagy in 4T1 cells by 
exposure to doxorubicin (Dox). Autophagy assessment is based on acridine orange 
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vacuole formation and quantification (Figures 26A and 26B) . Functional autophagy was 
further confirmed by p62/SQSTM1 degradation (Figure 26C) which indicates that fusion 
of phagosomes with lysosomes takes place and contents of the vesicles are degraded. 
Autophagy inhibition by chloroquine is shown by failure of lysosomal acidification and 
accumulation of phagosomes (Figure 26A and 26B) and further confirmed by the 
accumulation of LC3B II protein (Figure 26D). 
Senescence induction was confirmed based on β-galactosidase staining (Figure 26E) 
and quantification by flow cytometry (Figure 26F). Pharmacologic inhibition of autophagy 
did not interfere with the induction of senescence in 4T1 cells as SA-β-gal staining was 
prominent under both conditions: cells exposed to Dox alone, and cells exposed to the 
combination of Dox and CQ (Figure 26E). Furthermore, the percentage of C12FDG-
positive population was essentially identical when quantified by flow cytometry for cells 
exposed to Dox alone or to Dox and CQ drug combination (Figure 26F).  
 
 
Silencing of autophagy did not sensitize cells to apoptosis and did not decrease 
senescence.    
The nature of autophagy induced by Dox in the 4T1 cells was shown to be nonprotective. 
Genetic inhibition of autophagy was achieved by shAtg5 (Figure 27A). Successful 
Inhibition of autophagy was confirmed when doxorubicin treated shAtg5 cells did not show 
significant accumulation of LC3BII compared to shControl (Figure 27B). Silencing of Atg5 
did not lead to decreased cell survival based on colony formation (Figure 27C) 
Furthermore, autophagy competent 4T1 and cells in which autophagy was silenced 
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autophagy undergo apoptosis at the same rate after exposure to doxorubicin (Figure 
27D) 
Similar to pharmacologic inhibition (Figures 27E and 27F) genetic silencing of autophagy 
did not interfere with induction of senescence as cells treated with doxorubicin showed 
increase in β-galactosidase staining in both, shControl and shAtg5 cells and similar 
percent of C12FDG-positive population (Figures 27E and 27F). 
 
Inhibition of autophagy does not prevent 4T1 tumor cells from undergoing 
senescent growth arrest and does not prevent proliferative recovery 
Senescence was a primary response to treatment with doxorubicin as cells showed only 
marginal apoptosis of about 15% (Figure 27D) but significant increase in C12FDG-positive 
about 70-80% (Figures 26F and 27E). Upon exposure to the drug 4T1cells entered a 
state of prolonged growth arrest, then, cell regained proliferative capacity and formed new 
colonies. Inhibition of autophagy with chloroquine did not prevent senescent growth arrest 
and recovery (Figure 28A). Consistent with pharmacologic inhibition genetic silencing of 
autophagy by shAtg5 did not interfere with growth arrest and did not impact recovery 
(Figure 28B).    
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Figure 26. Induction of autophagy and senescence in response to doxorubicin 
exposure  in 4T1 mouse mammary tumor cells. A. Fluorescence microscopy images 
showing increased in acridine orange staining in cells treated with Dox (1 µM). 4T1 cells were 
pre-treated with CQ (10 µM) for 3 hours followed by 2-hour exposure to Dox with or without 
CQ. B. Quantification of autophagic cells by FACS analysis in response to Dox treatment 
showing accumulation of AO positive cells that it further enhanced by inhibition of acidic 
degradation by CQ. C. Induction of autophagy confirmed by Western Blot showing 
degradation of p62/SQSTM1 protein. D. Blockade of autophagic flux by chloroquine resulting 
in accumulation of LC3BII protein. E. Induction of senescence determined by elevated 
Senescence-associated b-galactosidase staining in 4T1 cells treated with 1 µM Dox (20x 
objective). F. Quantification of senescence by FACS analysis based on C12FDG staining of 
4T1 cells.   
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Figure 27. Doxorubicin induces nonprotective autophagy that is dissociate from 
senescence. A. Knockdown of Atg5 in 4T1 cells confirmed by Western Blot. B.  Western 
Blot of Atg5 deficient 4T1 exposed to Dox showing conversion of LC3BI to LC3BII in WT 
cells, accumulation of LC3BI with decreased LC3BII in autophagy deficient cells. C. Colony 
formation assay comparing clonogenic survival of shControl and shAtg5 4T1 cells in 
response to multiple Dox concentrations.  D.  Assessment of apoptosis by FACS analysis 
24 hours post-treatment with Dox using APC/7AAD (Annexin 5/ PI equivalent) dye. Genetic 
inhibition of autophagy did not result in increased apoptosis. E. Percent senescence 
quantified based on C12FDG staining 48 hours after exposure of shControl cells and shAtg5 
cells to Dox. F. Induction of senescence determined by Senescence-associated b-
galactosidase staining in shControl and shAtg5 4T1 cells treated with 1 µM Dox (20x 
objective). 
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Figure 28. Senescent growth arrest and proliferative recovery occur independently 
from autophagy. A. Temporal response to Dox in 4T1 cells after pharmacological 
inhibition of autophagy with CQ. Viable cell number was determined at the indicated time 
points after treatment with Dox in combination with CQ (10 µM).  B. Temporal assessment 
of growth arrest followed by proliferative recovery in shControl and shAtg5 4T1 cells. Viable 
cell number was determined at the indicated time points after treatment with doxorubicin. 
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D. Discussion 
 
As discussed before, both senescence and autophagy are major outcomes of most 
cytotoxic therapies. [142],[143] This study has shown, that apoptosis is not the main 
outcome of doxorubicin treatment, rather majority of cells undergo prolonged growth 
arrest. We determined that senescence as a result of exposure to DNA damaging agent 
is, in fact, primary response.   
Because both autophagy and senescence are result of severe cell stress such as DNA 
damage, it is not unexpected that mechanisms and pathways of their induction are 
connected. [144]  
As senescent cells remain metabolically active, it is logical to consider that autophagy 
serves to provide nutrients and maintain the metabolic function. Some studies show that 
autophagy, in fact, does contribute to the maintenance of dormant cells. [145] 
Although multiple studies identify autophagy as a cytoprotective mechanism, our results 
indicate that blockade of autophagy does not result in higher cell death, it also did not 
show to have an impact on duration of the growth arrest or neoplastic escape form 
senescence.      
Consequently, while robust autophagy is induced by doxorubicin and occurs in parallel 
with senescence, it does not appear to be a determinant factor in tumor cell’s fate 
following chemotherapy. This may be related to the fact that the autophagy is 
nonprotective in function [146]  
Taken together, these data indicate that neither the promotion or maintenance of 
senescence or recovery from senescence are dependent on promotion of autophagy. 
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These results have several implications. One is that if autophagy induced by 
chemotherapy is nonprotective, combining autophagy inhibition with cancer therapeutics 
are likely to be unsuccessful as the nature of autophagy cannot yet be predicted. 
Interestingly  studies that showed  involvement of autophagy in promoting an effective 
antitumor immune response following chemotherapy also identified the nonprotective 
form of autophagy [147].  
 The second implication is that senescence as a common response to therapy appears 
to be independent of autophagy. Thus, targeting autophagy in models of tumor dormancy 
and recurrence may not be a winning strategy.  
Although senescence and autophagy often occur in concert, they can play very different 
roles in the outcome of treatments. Thus, it is wise to consider both as independent 
processes when each can be modulated differently to achieve optimal outcome.   
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